

**Infectious Diseases Society of America 2026 Guidance on the Treatment of
Antimicrobial-Resistant Gram-Negative Infections**

Pranita D. Tamma¹, Robert A. Bonomo², Emily L. Heil³, Julie Ann Justo⁴,
Michael J. Satlin⁵, & Amy J. Mathers⁶

References

1. Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* **2022**; 399(10325): 629–55.
2. Collaborators GBDAR. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. *Lancet* **2024**; 404(10459): 1199–226.
3. de Kraker MEA, Lipsitch M. Burden of Antimicrobial Resistance: Compared to What? *Epidemiol Rev* **2022**; 43(1): 53–64.
4. Wolford H, McCarthy NL, Baggs J, et al. Antimicrobial-Resistant Infections in Hospitalized Patients. *JAMA Netw Open* **2025**; 8(3): e2462059.
5. Lockowitz CR, Hsu AJ, Chiotos K, et al. Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children. *J Pediatric Infect Dis Soc* **2025**; 14(2).
6. MacFadden DR, Coburn B, Shah N, et al. Utility of prior cultures in predicting antibiotic resistance of bloodstream infections due to Gram-negative pathogens: a multicentre observational cohort study. *Clin Microbiol Infect* **2018**; 24(5): 493–9.
7. Bakhit M, Hoffmann T, Scott AM, Beller E, Rathbone J, Del Mar C. Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis. *BMC Med* **2018**; 16(1): 126.
8. Blagojevic C, Brown KA, Diong C, et al. Long-term Risk of Infection Among Patients Colonized With Antimicrobial-Resistant Pathogens: A Population-wide Cohort Study. *Open Forum Infect Dis* **2024**; 11(12): ofae712.
9. de Nies L, Kobras CM, Stracy M. Antibiotic-induced collateral damage to the microbiota and associated infections. *Nat Rev Microbiol* **2023**; 21(12): 789–804.
10. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. *JAMA Intern Med* **2017**; 177(9): 1308–15.
11. Soto CL, Hsu AJ, Lee JH, et al. Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study. *Clin Infect Dis* **2024**; 78(1): 27–30.

12. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. <https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/> Accessed December 29, 2025.
13. Heil EL, Bork JT, Abbo LM, et al. Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process. *Open Forum Infect Dis* **2021**; 8(10): ofab434.
14. Tamma PD, Smith TT, Adebayo A, et al. Prevalence of bla(CTX-M) Genes in Gram-Negative Bloodstream Isolates across 66 Hospitals in the United States. *J Clin Microbiol* **2021**; 59(6).
15. Castanheira M, Kimbrough JH, DeVries S, Mendes RE, Sader HS. Trends of beta-Lactamase Occurrence Among *Escherichia coli* and *Klebsiella pneumoniae* in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by beta-Lactamase Type. *Open Forum Infect Dis* **2023**; 10(2): ofad038.
16. Pham TM, Zhang Y, Nevers M, et al. Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22). *Lancet Infect Dis* **2024**; 24(12): 1333–46.
17. Bush K, Bradford PA. Epidemiology of beta-Lactamase-Producing Pathogens. *Clin Microbiol Rev* **2020**; 33(2).
18. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. *Antimicrob Agents Chemother* **2014**; 58(2): 833–8.
19. Castanheira M, Simner PJ, Bradford PA. Extended-spectrum beta-lactamases: an update on their characteristics, epidemiology and detection. *JAC Antimicrob Resist* **2021**; 3(3): dlab092.
20. Hareza DA, Cosgrove SE, Simner PJ, et al. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum beta-Lactamase-Producing Enterobacterales Bloodstream Infections? *Clin Infect Dis* **2024**; 78(5): 1103–10.
21. Clinical and Laboratory Standards Institute. 2026. Performance standards for antimicrobial susceptibility testing, 36th ed. CLSI M100. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Henderson A, Paterson DL, Chatfield MD, et al. Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study. *Clin Infect Dis* **2021**; 73(11): e3842–e50.
23. Hopkins KL, Batchelor MJ, Liebana E, Deheer-Graham AP, Threlfall EJ. Characterisation of CTX-M and AmpC genes in human isolates of *Escherichia coli* identified between 1995 and 2003 in England and Wales. *Int J Antimicrob Agents* **2006**; 28(3): 180–92.

24. Hareza DA, Bergman Y, Jacobs E, et al. Establishing the Optimal Ceftriaxone MIC for Predicting ESBL Production in Bloodstream Infections. *Open Forum Infect Dis* **2025**; 12(9): ofaf490.
25. Talan DA, Takhar SS, Krishnadasan A, et al. Emergence of Extended-Spectrum beta-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States. *Ann Emerg Med* **2021**; 77(1): 32–43.
26. Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? *Antimicrob Agents Chemother* **2019**; 63(1).
27. Jenrette JE, Coronato K, Miller MA, Molina KC, Quinones A, Jacknin G. Prospective evaluation of single-dose aminoglycosides for treatment of complicated cystitis in the emergency department. *Acad Emerg Med* **2024**; 31(7): 649–55.
28. Watkins RR, Thapaliya D, Lemonovich TL, Bonomo RA. Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea. *J Antimicrob Chemother* **2023**; 78(5): 1137–42.
29. Hackel MA, Karlowsky JA, Sahm DF, West JM, Scangarella-Oman NE. In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus. *Antimicrob Agents Chemother* **2025**; 69(6): e0029625.
30. Scangarella-Oman NE, Butler DL, Breton J, et al. Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). *Antimicrob Agents Chemother* **2025**; 69(10): e0164024.
31. Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. *Lancet* **2024**; 403(10428): 741–55.
32. Das A, Alam U, Khan AS, et al. Efficacy and safety of Gepotidacin for urogenital infections: a systematic review and meta-analysis of randomized controlled trials. *Infection* **2026**.
33. Ahlstrand J, Maatouk I, Doanh LH, et al. High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-24. *J Antimicrob Chemother* **2026**; 81(1).
34. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. *J Antimicrob Chemother* **2014**; 69(12): 3259–62.
35. Bruyndonckx R, Latour K, Atud GA, et al. Time trend of prevalence and susceptibility to nitrofurantoin of urinary MDR Escherichia coli from outpatients. *J Antimicrob Chemother* **2019**; 74(11): 3264–7.

36. Tutone M, Bjerklund Johansen TE, Cai T, Mushtaq S, Livermore DM. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study. *Int J Antimicrob Agents* **2022**; 59(5): 106574.
37. Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. *JAMA* **2018**; 319(17): 1781–9.
38. Sougakoff W, Jarlier VV. Comparative potency of mecillinam and other beta-lactam antibiotics against *Escherichia coli* strains producing different beta-lactamases. *J Antimicrob Chemother* **2000**; 46 Suppl A: 9–14.
39. Lodise TP, Kaye KS, Santerre Henriksen A, Kahlmeter G. Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens. *Open Forum Infect Dis* **2024**; 11(6): ofae296.
40. Raja NS. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. *Int J Clin Pract* **2019**; 73(9): 1–5.
41. Vik I, Bollestad M, Grude N, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. *PLoS Med* **2018**; 15(5): e1002569.
42. Menday AP. Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. *Int J Antimicrob Agents* **2000**; 13(3): 183–7.
43. Bollestad M, Grude N, Solhaug S, et al. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing *Escherichia coli*: a prospective, multicentre, observational cohort study. *J Antimicrob Chemother* **2018**; 73(9): 2503–9.
44. Kaye KS, Santerre Henriksen A, Sommer M, Frimodt-Moller N. Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review. *Clin Infect Dis* **2025**; 80(2): 280–99.
45. Jacobs MR, Abdelhamed AM, Good CE, et al. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum beta-Lactamases and Carbapenemases. *Antimicrob Agents Chemother* **2019**; 63(1).
46. Dunne MW, Aronin SI, Das AF, et al. Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial. *Clin Infect Dis* **2023**; 76(1): 66–77.
47. Probenecid. FDA Drug Label. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2375d90-4132-4fb6-aea7-c4f9d11e98d5>. Accessed December 31, 2025.

48. Zalmanovici Trestioreanu A, Green H, Paul M, Yaphe J, Leibovici L. Antimicrobial agents for treating uncomplicated urinary tract infection in women. *Cochrane Database Syst Rev* **2010**; 2010(10): CD007182.
49. Critchley IA, Cotroneo N, Pucci MJ, Mendes R. The burden of antimicrobial resistance among urinary tract isolates of *Escherichia coli* in the United States in 2017. *PLoS One* **2019**; 14(12): e0220265.
50. Butler AM, Durkin MJ, Keller MR, Ma Y, Powderly WG, Olsen MA. Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection. *Clin Infect Dis* **2022**; 74(8): 1408–18.
51. Sastry S, Clarke LG, Alrowais H, Querry AM, Shutt KA, Doi Y. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. *Antimicrob Agents Chemother* **2015**; 59(12): 7355–61.
52. Ito R, Mustapha MM, Tomich AD, et al. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal *fosA* Gene. *mBio* **2017**; 8(4).
53. Elliott ZS, Barry KE, Cox HL, et al. The Role of *fosA* in Challenges with Fosfomycin Susceptibility Testing of Multispecies *Klebsiella pneumoniae* Carbapenemase-Producing Clinical Isolates. *J Clin Microbiol* **2019**; 57(10).
54. Abbott IJ, Dekker J, van Gorp E, et al. Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections. *J Antimicrob Chemother* **2020**; 75(4): 988–96.
55. Wenzler E, Bleasdale SC, Sikka M, et al. Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. *Antimicrob Agents Chemother* **2018**; 62(8).
56. Rouphael N, Winokur P, Keefer MC, et al. Daily fosfomycin versus levofloxacin for complicated urinary tract infections. *mBio* **2023**; 14(5): e0167723.
57. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. *JAMA* **2005**; 293(8): 949–55.
58. Campbell JD, Lewis JS, 2nd, McElmeel ML, Fulcher LC, Jorgensen JH. Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae. *J Clin Microbiol* **2012**; 50(3): 1023–6.
59. Thomson GK, Ayaz M, Lutes K, Thomson KS. An Improved Extended-Spectrum-beta-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate. *J Clin Microbiol* **2018**; 56(1).
60. Estebanez A, Pascual R, Gil V, Ortiz F, Santibanez M, Perez Barba C. Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. *Eur J Clin Microbiol Infect Dis* **2009**; 28(12): 1457–64.

61. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycyclines. *J Antimicrob Chemother* **2006**; 58(2): 256–65.
62. Mukerji AC, Sharma MM, Taneja OP, Saxena SN, Bhatnagar RK, Ghosh-Ray B. A clinical trial of alpha-6-deoxyoxytetracycline (doxycycline) in the treatment of urinary tract infections. *Chemotherapy* **1969**; 14(2): 77–85.
63. Musher DM, Minuth JN, Thorsteinsson SB, Holmes T. Effectiveness of achievable urinary concentrations of tetracyclines against "tetracycline-resistant" pathogenic bacteria. *J Infect Dis* **1975**; 131 Suppl: S40–4.
64. Sandberg T, Skoog G, Hermansson AB, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. *Lancet* **2012**; 380(9840): 484–90.
65. Ren H, Li X, Ni ZH, et al. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. *Int Urol Nephrol* **2017**; 49(3): 499–507.
66. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA* **2000**; 283(12): 1583–90.
67. Morrissey I, Hawser S, Kothari N, et al. Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates. *J Glob Antimicrob Resist* **2024**; 38: 71–82.
68. Kaye KS, Belley A, Barth P, et al. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial. *JAMA* **2022**; 328(13): 1304–14.
69. Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. *Clin Infect Dis* **2019**; 69(12): 2045–56.
70. Sojo-Dorado J, Lopez-Hernandez I, Rosso-Fernandez C, et al. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. *JAMA Netw Open* **2022**; 5(1): e2137277.
71. Tamma PD, Bonomo RA, Stiefel U. The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante's Forest Dark. *JAMA Netw Open* **2022**; 5(1): e2138691.
72. Bergeron MG, Trottier S. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution. *Antimicrob Agents Chemother* **1979**; 15(5): 635–41.

73. Bertino JS, Jr., Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. *J Infect Dis* **1993**; 167(1): 173–9.
74. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. *Clin Infect Dis* **2007**; 45(6): 753–60.
75. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. *N Engl J Med* **2019**; 380(8): 729–40.
76. Mohsenpour B, Ahmadi A, Azizzadeh H, et al. Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with *E. coli*: a double-blind clinical trial. *BMC Res Notes* **2024**; 17(1): 38.
77. Elbaz M, Zadka H, Weiss-Meilik A, Ben-Ami R. Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis. *J Antimicrob Chemother* **2020**; 75(8): 2307–13.
78. Vidal L, Gafter-Gvili A, Borok S, Fraser A, Leibovici L, Paul M. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* **2007**; 60(2): 247–57.
79. Chou A, Welch E, Hunter A, Trautner BW. Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review. *Drugs* **2022**; 82(4): 407–38.
80. Dunne MW, Aronin SI, Das AF, et al. Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. *Clin Infect Dis* **2023**; 76(1): 78–88.
81. Ten Doesschate T, Kuiper S, van Nieuwkoop C, et al. Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. *Clin Infect Dis* **2022**; 75(2): 221–9.
82. Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With *E coli* or *Klebsiella pneumoniae* Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. *JAMA* **2018**; 320(10): 984–94.
83. Liebchen U, Kratzer A, Wicha SG, Kees F, Kloft C, Kees MG. Unbound fraction of ertapenem in intensive care unit patients. *J Antimicrob Chemother* **2014**; 69(11): 3108–11.
84. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. *J Antimicrob Chemother* **2007**; 59(2): 277–84.
85. Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. *Int J Antimicrob Agents* **2009**; 33(5): 432–6.

86. Shah S, Clarke LG, Balasubramani GK, Peng L, Smith BJ, Shields RK. Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* **2025**; 80(7): 1823–7.
87. Zusman O, Farbman L, Tredler Z, et al. Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study. *Clin Microbiol Infect* **2015**; 21(1): 54–8.
88. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* **2011**; 70(1): 150–3.
89. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS, Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. *Antimicrob Agents Chemother* **2006**; 50(4): 1222–7.
90. Goutelle S, Valour F, Gagnieu MC, et al. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. *J Antimicrob Chemother* **2018**; 73(4): 987–94.
91. Lass J, Tamme K, Kipper K, Starkopf J. Dosing of Ertapenem in an Extreme Obesity: A Case Report of 250 kg Patient. *Case Rep Crit Care* **2017**; 2017: 5310768.
92. Das S, Fitzgerald R, Ullah A, et al. Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. *Antimicrob Agents Chemother* **2020**; 65(1).
93. Papp-Wallace KM, Bethel CR, Caillon J, et al. Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent beta-Lactam-beta-Lactamase Inhibitor Combination. *Antimicrob Agents Chemother* **2019**; 63(5).
94. Dunne MW, Aronin SI, Das AF, et al. A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections. *Clin Microbiol Infect* **2025**; 31(3): 396–401.
95. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. *Antimicrob Agents Chemother* **1993**; 37(4): 851–8.
96. Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? *J Antimicrob Chemother* **2012**; 67(7): 1569–77.
97. Zhou M, Wang Y, Liu C, et al. Comparison of five commonly used automated susceptibility testing methods for accuracy in the China Antimicrobial Resistance Surveillance System (CARSS) hospitals. *Infect Drug Resist* **2018**; 11: 1347–58.
98. Livermore DM, Day M, Cleary P, et al. OXA-1 beta-lactamase and non-susceptibility to penicillin/beta-lactamase inhibitor combinations among ESBL-producing *Escherichia coli*. *J Antimicrob Chemother* **2019**; 74(2): 326–33.

99. Burgess DS, Hall RG, 2nd. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* **2004**; 49(1): 41–6.
100. Harada Y, Morinaga Y, Kaku N, et al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing *Klebsiella pneumoniae*. *Clin Microbiol Infect* **2014**; 20(11): O831–9.
101. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Antimicrob Agents Chemother* **2001**; 45(12): 3548–54.
102. Monogue ML, Heil EL, Aitken SL, Pogue JM. The role of tazobactam-based combinations for the management of infections due to extended-spectrum beta-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* **2021**; 41(10): 864–80.
103. Piperacillin-tazobactam. FDA Drug Label.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6>. Accessed March 7, 2026.
104. Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *BMC Infect Dis* **2017**; 17(1): 404.
105. Sutton SP, Reinert JP. Evaluation of the Efficacy of Piperacillin/Tazobactam in Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae Urinary Tract Infections: A Systematic Review of the Literature. *Ann Pharmacother* **2025**; 59(7): 648–56.
106. NCT03671967. PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN). Accessed December 31, 2025.
107. Zhang H, Xu J, Xiao Q, et al. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. *Int J Infect Dis* **2023**; 128: 194–204.
108. Mansson TS, Askemyr A, Sunnerhagen T, Tham J, Riesbeck K, Mellhammar L. Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study. *Infection* **2025**; 53(5): 1769–77.
109. Capsoni N, Bettina M, Bellone B, et al. Empirical piperacillin/tazobactam vs carbapenems to treat bloodstream infections due to ESBL enterobacterales: a propensity score-matched observational study conducted in an emergency department in Northern Italy. *Infect Dis (Lond)* **2025**: 1–12.
110. Rebeck JA, Olsen KM, Fey PD, Bergman KL, Rupp ME. In vitro activities of parenteral beta-lactam antimicrobials against TEM-10-, TEM-26- and SHV-5-derived extended-spectrum beta-lactamases expressed in an isogenic *Escherichia coli* host. *J Antimicrob Chemother* **2000**; 46(3): 461–4.

111. Sirot D. Extended-spectrum plasmid-mediated beta-lactamases. *J Antimicrob Chemother* **1995**; 36 Suppl A: 19–34.
112. Smith KP, Brennan-Krohn T, Weir S, Kirby JE. Improved Accuracy of Cefepime Susceptibility Testing for Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae with an On-Demand Digital Dispensing Method. *J Clin Microbiol* **2017**; 55(2): 470–8.
113. Cefepime. FDA Drug Label. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02aa374f-37b4-456a-b5de-cfd3bbb6ce6e>. Accessed December 31, 2025.
114. Kim SA, Altshuler J, Paris D, Fedorenko M. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. *Int J Antimicrob Agents* **2018**; 51(1): 155–8.
115. Branton AC, Vu CH, Venugopalan V, et al. Re-evaluation of cefepime or piperacillin/tazobactam to decrease use of carbapenems in ESBL-producing Enterobacterales urinary tract infections (REDUCE-UTI). *JAC Antimicrob Resist* **2023**; 5(2): dlad021.
116. Wang R, Cosgrove SE, Tschudin-Sutter S, et al. Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Bacteremia. *Open Forum Infect Dis* **2016**; 3(3): ofw132.
117. Lee NY, Lee CC, Li CW, et al. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates. *Antimicrob Agents Chemother* **2015**; 59(12): 7558–63.
118. Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother* **2012**; 56(7): 3936–42.
119. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. *Clin Infect Dis* **2013**; 56(4): 488–95.
120. Frescas BE, McCoy CM, Kirby J, Bowden R, Mercurio NJ. Outcomes associated with empiric cefepime for bloodstream infections caused by ceftriaxone-resistant, cefepime-susceptible *Escherichia coli* and *Klebsiella pneumoniae*. *Int J Antimicrob Agents* **2023**; 61(5): 106762.
121. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. *Antimicrob Agents Chemother* **2003**; 47(11): 3442–7.
122. Stewart AG, Cottrell K, Henderson A, et al. In Vitro Activity of Cefotetan against ESBL-Producing *Escherichia coli* and *Klebsiella pneumoniae* Bloodstream Isolates from the MERINO Trial. *Microbiol Spectr* **2021**; 9(1): e0022621.

123. Kusumoto M, Kanao Y, Narita H, et al. In vitro efficacy of cephamycins against multiple extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Enterobacter cloacae* isolates from dogs and cats. *J Vet Med Sci* **2023**; 85(6): 653–6.
124. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing *Klebsiella pneumoniae* bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. *J Antimicrob Chemother* **2006**; 58(5): 1074–7.
125. Yang CC, Li SH, Chuang FR, et al. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing *Klebsiella pneumoniae* in patients on maintenance hemodialysis. *BMC Infect Dis* **2012**; 12: 206.
126. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Int J Infect Dis* **2013**; 17(3): e159–63.
127. Pilmis B, Parize P, Zahar JR, Lortholary O. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae. *Eur J Clin Microbiol Infect Dis* **2014**; 33(8): 1263–5.
128. Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing *Escherichia coli* bacteremia. *Antimicrob Agents Chemother* **2015**; 59(9): 5107–13.
129. Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. *BMC Infect Dis* **2016**; 16(1): 427.
130. Lee CH, Su LH, Chen FJ, et al. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella pneumoniae* with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study. *Int J Antimicrob Agents* **2015**; 46(6): 610–5.
131. Hayakawa K, Matsumura Y, Uemura K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *Antimicrob Agents Chemother* **2023**; 67(10): e0051023.
132. Takemura W, Tashiro S, Hayashi M, et al. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments. *Pharm Res* **2021**; 38(11): 1839–46.
133. Randomised Controlled Trial of Meropenem versus Cefmetazole for definitive treatment of bloodstream infections due to ESBL- producing *Escherichia coli*. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055809. Accessed December 31, 2025.
134. Senard O, Lafaurie M, Lesprit P, et al. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing *Escherichia coli*: a multicenter

retrospective cohort study with propensity score analysis. *Eur J Clin Microbiol Infect Dis* **2020**; 39(1): 121–9.

135. Chabert P, Provoost J, Cohen S, et al. Pharmacokinetics, efficacy and tolerance of ceftazidime in the treatment of ceftazidime-susceptible extended-spectrum beta-lactamase producing Enterobacteriales infections in critically ill patients: a retrospective single-center study. *Ann Intensive Care* **2022**; 12(1): 90.
136. Bush K, Bradford PA. Interplay between beta-lactamases and new beta-lactamase inhibitors. *Nat Rev Microbiol* **2019**; 17(5): 295–306.
137. Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC beta-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. *Antimicrob Agents Chemother* **2016**; 60(5): 2849–57.
138. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. *Lancet Infect Dis* **2016**; 16(6): 661–73.
139. Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK. Molecular beta-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. *Antimicrob Agents Chemother* **2017**; 61(6).
140. Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK. Characterization of beta-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against beta-Lactamase Producers. *Antimicrob Agents Chemother* **2019**; 63(6).
141. Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-beta-Lactamase- and AmpC-Producing Enterobacteriales?: a Systematic Review and Meta-analysis. *Antimicrob Agents Chemother* **2020**; 65(1).
142. Torres A, Zhong N, Pacht J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. *Lancet Infect Dis* **2018**; 18(3): 285–95.
143. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and *Pseudomonas aeruginosa* with various resistance patterns isolated in U.S. Hospitals (2011-2012). *Antimicrob Agents Chemother* **2013**; 57(12): 6305–10.
144. Sutherland CA, Nicolau DP. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* From US Hospitals. *Clin Ther* **2015**; 37(7): 1564–71.

145. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and *Pseudomonas aeruginosa* collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. *Diagn Microbiol Infect Dis* **2018**; 92(2): 158–63.
146. Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and *Pseudomonas aeruginosa* with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. *Microb Drug Resist* **2018**; 24(5): 563–77.
147. Sader HS, Castanheira M, Streit JM, Flamm RK. Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). *Diagn Microbiol Infect Dis* **2019**; 95(3): 114850.
148. Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). *Diagn Microbiol Infect Dis* **2020**; 96(3): 114833.
149. Nicasio AM, VanScoy BD, Mendes RE, et al. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. *Antimicrob Agents Chemother* **2016**; 60(4): 2075–80.
150. VanScoy B, Mendes RE, Nicasio AM, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. *Antimicrob Agents Chemother* **2013**; 57(6): 2809–14.
151. Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a pooled analysis of Phase 3 clinical trials. *J Antimicrob Chemother* **2017**; 72(1): 268–72.
152. Kollef MH, Novacek M, Kivistik U, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* **2019**; 19(12): 1299–311.
153. Martin-Loeches I, Timsit JF, Kollef MH, et al. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. *J Antimicrob Chemother* **2022**; 77(4): 1166–77.
154. Johnson JW, Fisher JF, Mobashery S. Bacterial cell-wall recycling. *Ann N Y Acad Sci* **2013**; 1277(1): 54–75.
155. Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ, Antibacterial Resistance Leadership G. A Primer on AmpC beta-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. *Clin Infect Dis* **2019**; 69(8): 1446–55.

156. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev **2009**; 22(1): 161–82, Table of Contents.
157. Philippon A, Arlet G, Labia R, Iorga BI. Class C beta-Lactamases: Molecular Characteristics. Clin Microbiol Rev **2022**; 35(3): e0015021.
158. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis **1995**; 21(5): 1107–13.
159. Honore N, Nicolas MH, Cole ST. Inducible cephalosporinase production in clinical isolates of *Enterobacter cloacae* is controlled by a regulatory gene that has been deleted from *Escherichia coli*. EMBO J **1986**; 5(13): 3709–14.
160. Hareza DA, Bergman Y, Jacobs E, et al. Molecular epidemiology of beta-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States. Antimicrob Agents Chemother **2025**; 69(3): e0125824.
161. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother **2002**; 46(1): 1–11.
162. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob Agents Chemother **2004**; 48(2): 533–7.
163. Lindberg F, Westman L, Normark S. Regulatory components in *Citrobacter freundii* ampC beta-lactamase induction. Proc Natl Acad Sci U S A **1985**; 82(14): 4620–4.
164. Underwood S, Avison MB. *Citrobacter koseri* and *Citrobacter amalonaticus* isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother **2004**; 53(6): 1076–80.
165. Matsen JM, Blazevec DJ, Ryan JA, Ewing WH. Characterization of indole-positive *Proteus mirabilis*. Appl Microbiol **1972**; 23(3): 592–4.
166. Choi SH, Lee JE, Park SJ, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother **2008**; 52(3): 995–1000.
167. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med **1991**; 115(8): 585–90.
168. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among *Enterobacter* spp. Antimicrob Agents Chemother **2001**; 45(9): 2628–30.
169. Kohlmann R, Bahr T, Gatermann SG. Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC beta-lactamase. J Antimicrob Chemother **2018**; 73(6): 1530–6.

170. Girlich D, Naas T, Bellais S, Poirel L, Karim A, Nordmann P. Heterogeneity of AmpC cephalosporinases of *Hafnia alvei* clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes. *Antimicrob Agents Chemother* **2000**; 44(11): 3220–3.
171. Lazarus JE, Wang Y, Waldor MK, Hooper DC. Divergent genetic landscapes drive lower levels of AmpC induction and stable de-repression in *Serratia marcescens* compared to *Enterobacter cloacae*. *Antimicrob Agents Chemother* **2024**; 68(1): e0119323.
172. Maillard A, Dortet L, Delory T, Lafaurie M, Bleibtreu A, Treatment of Amp CpEsg. Mutation Rate of AmpC beta-Lactamase-Producing Enterobacterales and Treatment in Clinical Practice: A Word of Caution. *Clin Infect Dis* **2024**; 79(1): 52–5.
173. Mulbah JL, Kenney RM, Tibbetts RJ, Shallal AB, Veve MP. Ceftriaxone versus cefepime or carbapenems for definitive treatment of low-risk AmpC-Harboring Enterobacterales bloodstream infections in hospitalized adults: A retrospective cohort study. *Diagn Microbiol Infect Dis* **2025**; 111(1): 116557.
174. Liu C, Wang X, Chen Y, et al. Three *Yersinia enterocolitica* AmpD Homologs Participate in the Multi-Step Regulation of Chromosomal Cephalosporinase, AmpC. *Front Microbiol* **2016**; 7: 1282.
175. Seoane A, Francia MV, Garcia Lobo JM. Nucleotide sequence of the ampC-ampR region from the chromosome of *Yersinia enterocolitica*. *Antimicrob Agents Chemother* **1992**; 36(5): 1049–52.
176. Liu Z, Shen S, Zhang X, et al. Identification of CMY-190, a novel chromosomally encoded AmpC beta-lactamase, and plasmid-encoded KPC-2 in a clinical isolate of *Citrobacter youngae*. *Front Microbiol* **2025**; 16: 1526882.
177. Sanders CC, Bradford PA, Ehrhardt AF, et al. Penicillin-binding proteins and induction of AmpC beta-lactamase. *Antimicrob Agents Chemother* **1997**; 41(9): 2013–5.
178. Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C beta-lactamases. *Antimicrob Agents Chemother* **2002**; 46(12): 3978–80.
179. Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. *Antimicrob Agents Chemother* **2001**; 45(10): 2831–7.
180. Kurpiel PM, Hanson ND. Point mutations in the inc antisense RNA gene are associated with increased plasmid copy number, expression of blaCMY-2 and resistance to piperacillin/tazobactam in *Escherichia coli*. *J Antimicrob Chemother* **2012**; 67(2): 339–45.
181. Weber DA, Sanders CC. Diverse potential of beta-lactamase inhibitors to induce class I enzymes. *Antimicrob Agents Chemother* **1990**; 34(1): 156–8.
182. Akata K, Muratani T, Yatera K, et al. Induction of plasmid-mediated AmpC beta-lactamase DHA-1 by piperacillin/tazobactam and other beta-lactams in Enterobacteriaceae. *PLoS One* **2019**; 14(7): e0218589.
183. Sakurai Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawai T. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases. *J Antibiot (Tokyo)* **1990**; 43(4): 403–10.

184. Endimiani A, Doi Y, Bethel CR, et al. Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2. *Biochemistry* **2010**; 49(5): 1014–23.
185. Dahyot S, Mammeri H. Hydrolysis spectrum extension of CMY-2-like beta-lactamases resulting from structural alteration in the Y-X-N loop. *Antimicrob Agents Chemother* **2012**; 56(3): 1151–6.
186. Custodio MM, Sanchez D, Anderson B, Ryan KL, Walraven C, Mercier RC. Emergence of Resistance in *Klebsiella aerogenes* to Piperacillin-Tazobactam and Ceftriaxone. *Antimicrob Agents Chemother* **2021**; 65(2).
187. Hancock RE, Bellido F. Antibacterial in vitro activity of fourth generation cephalosporins. *J Chemother* **1996**; 8 Suppl 2: 31–6.
188. Negri MC, Baquero F. In vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer *Enterobacter cloacae* variants. *Clin Microbiol Infect* **1999**; 5 Suppl 1: S25–S8.
189. Fung-Tomc JC, Gradelski E, Huczko E, Dougherty TJ, Kessler RE, Bonner DP. Differences in the resistant variants of *Enterobacter cloacae* selected by extended-spectrum cephalosporins. *Antimicrob Agents Chemother* **1996**; 40(5): 1289–93.
190. Harris PN, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by *Enterobacter*, *Citrobacter* or *Serratia* species: a systematic review with meta-analysis. *J Antimicrob Chemother* **2016**; 71(2): 296–306.
191. Cheo HM, Ho DYK, Koh LP, Koh MCY, Ngiam JN, Lye DCB. Cefepime Versus Carbapenem Therapy for the Treatment of Invasive Infections With Inducible Chromosomal AmpC-Producing Enterobacterales: A Systematic Review and Meta-analysis. *Open Forum Infect Dis* **2025**; 12(7): ofaf413.
192. Hancock RE, Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. *J Antimicrob Chemother* **1992**; 29 Suppl A: 1–6.
193. Szabo D, Bonomo RA, Silveira F, et al. SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in *Enterobacter cloacae*. *J Clin Microbiol* **2005**; 43(10): 5058–64.
194. Hareza D, Simner PJ, Bergman Y, Jacobs E, Cosgrove SE, Tamma PD. The Frequency of Extended-Spectrum beta-Lactamase Genes Harbored by Enterobacterales Isolates at High Risk for Clinically Significant Chromosomal ampC Expression. *Open Forum Infect Dis* **2023**; 10(4): ofad175.
195. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. *Clin Infect Dis* **2013**; 57(6): 781–8.
196. Peters DM, Jr., Winter JB, Droege CA, Ernst NE, Liao S. Comparison of Ceftriaxone and Antipseudomonal beta-Lactam Antibiotics Utilized for Potential AmpC beta-Lactamase-Producing Organisms. *Hosp Pharm* **2021**; 56(5): 560–8.

197. Drozdinsky G, Neuberger A, Rakedzon S, et al. Treatment of Bacteremia Caused by *Enterobacter* spp.: Should the Potential for AmpC Induction Dictate Therapy? A Retrospective Study. *Microb Drug Resist* **2021**; 27(3): 410–4.
198. Derrick C, Bookstaver PB, Lu ZK, et al. Multicenter, Observational Cohort Study Evaluating Third-Generation Cephalosporin Therapy for Bloodstream Infections Secondary to *Enterobacter*, *Serratia*, and *Citrobacter* Species. *Antibiotics (Basel)* **2020**; 9(5).
199. Maillard A, Delory T, Bernier J, et al. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC beta-lactamase-producing *Enterobacterales*: A multi-centre retrospective propensity-weighted study. *Int J Antimicrob Agents* **2023**; 62(1): 106809.
200. Hilty M, Sendi P, Seiffert SN, et al. Characterisation and clinical features of *Enterobacter cloacae* bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy? *Int J Antimicrob Agents* **2013**; 41(3): 236–49.
201. Robin F, Auzou M, Bonnet R, et al. In Vitro Activity of Ceftolozane-Tazobactam against *Enterobacter cloacae* Complex Clinical Isolates with Different beta-Lactam Resistance Phenotypes. *Antimicrob Agents Chemother* **2018**; 62(9).
202. Cheng MP, Lee RS, Cheng AP, et al. Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. *Open Forum Infect Dis* **2019**; 6(7).
203. Lu B, Wong M, Ha D, et al. Piperacillin/tazobactam versus cefepime or carbapenems for ceftazidime-non-susceptible *Enterobacter cloacae*, *Klebsiella aerogenes*, *Citrobacter freundii*, *Serratia marcescens* and *Morganella morganii* bacteraemia in immunocompromised patients. *J Antimicrob Chemother* **2023**; 78(4): 1009–14.
204. da Cunha Ferreira T, Martins IS. Risk Factors of Death in Bloodstream Infections Caused by AmpC beta-Lactamase-Producing *Enterobacterales* in Patients with Neoplasia. *Infect Drug Resist* **2021**; 14: 3083–97.
205. Stewart AG, Paterson DL, Young B, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC beta-Lactamase-Producing *Enterobacter* spp, *Citrobacter freundii*, *Morganella morganii*, *Providencia* spp, or *Serratia marcescens*: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). *Open Forum Infect Dis* **2021**; 8(8): ofab387.
206. Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations. *Drugs* **2018**; 78(1): 65–98.
207. Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M. Characterization of *Enterobacter cloacae* and *Citrobacter freundii* species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. *JAC Antimicrob Resist* **2021**; 3(3): dlab136.

208. Torres A, Wible M, Tawadrous M, et al. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by beta-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme. *J Antimicrob Chemother* **2023**; 78(11): 2672–82.
209. Iregui A, Khan Z, Landman D, Quale J. Activity of Cefiderocol Against Enterobacterales, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* Endemic to Medical Centers in New York City. *Microb Drug Resist* **2020**; 26(7): 722–6.
210. Kawai A, McElheny CL, Iovleva A, et al. Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in *Enterobacter cloacae* Due to AmpC R2 Loop Deletion. *Antimicrob Agents Chemother* **2020**; 64(7).
211. Shields RK, Iovleva A, Kline EG, Kawai A, McElheny CL, Doi Y. Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in *Enterobacter cloacae* Complex Following Exposure to Cefepime. *Clin Infect Dis* **2020**; 71(10): 2713–6.
212. Shropshire WC, Endres BT, Borjan J, et al. High-level ceftazidime/avibactam resistance in *Escherichia coli* conferred by the novel plasmid-mediated beta-lactamase CMY-185 variant. *J Antimicrob Chemother* **2023**; 78(10): 2442–50.
213. Rodriguez-Pallares S, Blanco-Martin T, Lence E, et al. In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC beta-lactamase in *Klebsiella aerogenes*. *Antimicrob Agents Chemother* **2024**; 68(12): e0130724.
214. Barnes MD, Taracila MA, Rutter JD, et al. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in *Pseudomonas aeruginosa*. *mBio* **2018**; 9(6).
215. Tato M, Garcia-Castillo M, Bofarull AM, Canton R, Group CS. In vitro activity of ceftolozane/tazobactam against clinical isolates of *Pseudomonas aeruginosa* and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. *Int J Antimicrob Agents* **2015**; 46(5): 502–10.
216. Zhanel GG, Pozdirca M, Golden AR, et al. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. *Drugs* **2022**; 82(5): 533–57.
217. Aronin SI, Huband MD, Becker H, Fedler KA, Dunne MW. In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023. *J Glob Antimicrob Resist* **2025**; 44: 152–9.
218. Karlowsky JA, Adam HJ, Baxter MR, et al. In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of *Escherichia coli*. *Antimicrob Agents Chemother* **2019**; 63(1).
219. Walkty AJ, Karlowsky JA, Baxter MR, Lagace-Wiens PRS, Adam HJ, Zhanel GG. In vitro activity of sulopenem against 1880 bacterial pathogens isolated from Canadian patients with urinary tract infections (CANWARD, 2014-21). *J Antimicrob Chemother* **2022**; 77(12): 3414–20.

220. Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program. *J Antimicrob Chemother* **2023**; 78(6): 1559.
221. Hawser S, Morrissey I, Kothari N, Monti F, Henriksen AS. Activity of mecillinam against USA urinary tract clinical isolates from 2017 to 2020 including isolates resistant to comparator antibiotics. *J Glob Antimicrob Resist* **2024**; 39: 137–43.
222. Sabour S, Huang JY, Bhatnagar A, et al. Detection and Characterization of Targeted Carbapenem-Resistant Health Care-Associated Threats: Findings from the Antibiotic Resistance Laboratory Network, 2017 to 2019. *Antimicrob Agents Chemother* **2021**; 65(12): e0110521.
223. Zheng X, Zeng W, Liu Y, et al. Clinical characteristics, specific resistance patterns, and molecular mechanisms of carbapenem-resistant *Morganella morganii* isolates. *Front Cell Infect Microbiol* **2025**; 15: 1672736.
224. Neuwirth C, Siebor E, Duez JM, Pechinot A, Kazmierczak A. Imipenem resistance in clinical isolates of *Proteus mirabilis* associated with alterations in penicillin-binding proteins. *J Antimicrob Chemother* **1995**; 36(2): 335–42.
225. Shropshire WC, Aitken SL, Pifer R, et al. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. *J Antimicrob Chemother* **2021**; 76(2): 385–95.
226. Hamzaoui Z, Ocampo-Sosa A, Fernandez Martinez M, et al. Role of association of OmpK35 and OmpK36 alteration and bla(ESBL) and/or bla(AmpC) genes in conferring carbapenem resistance among non-carbapenemase-producing *Klebsiella pneumoniae*. *Int J Antimicrob Agents* **2018**; 52(6): 898–905.
227. van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. *Lancet Infect Dis* **2020**; 20(6): 731–41.
228. Sader HS, Mendes RE, Carvalhaes CG, Kimbrough JH, Castanheira M. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021). *Open Forum Infect Dis* **2023**; 10(2): ofad046.
229. Rankin DA, Stahl A, Sabour S, et al. Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023. *Ann Intern Med* **2025**.
230. Karlsson M, Lutgring JD, Ansari U, et al. Molecular Characterization of Carbapenem-Resistant Enterobacterales Collected in the United States. *Microb Drug Resist* **2022**; 28(4): 389–97.
231. Devinney K, Burton N, Alroy KA, et al. Notes from the Field: Increase in New Delhi Metallo-beta-Lactamase-Producing Carbapenem-Resistant Enterobacterales - New York City, 2019-2024. *MMWR Morb Mortal Wkly Rep* **2025**; 74(23): 401–3.

232. Warecki BA, Tomatis PE, Mojica MF, et al. Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents. *Chem Sci* **2025**.
233. Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a Rapid Molecular Test for *Klebsiella pneumoniae* Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. *Clin Infect Dis* **2022**; 75(12): 2066–75.
234. Ren H, Teng Y, Xu Z, et al. Enhanced Outcomes in Bacteremia Through Rapid Phenotype Identification of Carbapenemase-Producing Organisms. *Surg Infect (Larchmt)* **2025**.
235. Blosser SJ, Bhatnagar AS, Bollinger S, Giffen SR. Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory. *Clin Lab Med* **2025**; 45(1): 51–61.
236. Simner PJ, Pitout JDD, Dingle TC. Laboratory detection of carbapenemases among Gram-negative organisms. *Clin Microbiol Rev* **2024**; 37(4): e0005422.
237. Perez-Galera S, Bravo-Ferrer JM, Paniagua M, et al. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control study (EURECA). *EClinicalMedicine* **2023**; 57: 101871.
238. Sader HS, Mendes RE, Kimbrough JH, Kantro V, Castanheira M. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers. *Open Forum Infect Dis* **2023**; 10(2): ofad058.
239. Bland CM, Pai MP, Lodise TP. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. *Pharmacotherapy* **2018**; 38(12): 1229–38.
240. Tamma PD, Bergman Y, Jacobs EB, et al. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. *Infect Control Hosp Epidemiol* **2023**; 44(5): 762–7.
241. Falagas ME, Kontogiannis DS, Sargianou M, Kakoullis SA. In vitro antimicrobial activity and clinical use of trimethoprim-sulfamethoxazole for infections due to KPC-producing Gram-negative pathogens: a review. *Eur J Clin Microbiol Infect Dis* **2025**; 44(11): 2559–68.
242. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. *Int J Antimicrob Agents* **2011**; 37(5): 415–9.
243. Amladi AU, Abirami B, Devi SM, et al. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant Enterobacteriaceae causing urinary tract infections. *Indian J Med Res* **2019**; 149(2): 185–91.

244. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. *Clin Infect Dis* **2013**; 57(4): 524–31.
245. Lopez Montesinos I, Gomez-Zorrilla S, Palacios-Baena ZR, et al. Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant *Pseudomonas aeruginosa*: A Propensity Score-Adjusted and Matched Cohort Study. *Infect Dis Ther* **2022**; 11(1): 335–50.
246. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant *Klebsiella pneumoniae* from urine. *Antimicrob Agents Chemother* **2011**; 55(12): 5893–9.
247. Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity. *Antibiotics (Basel)* **2019**; 8(1).
248. Sadyrbaeva-Dolgova S, Garcia-Fumero R, Exposito-Ruiz M, Pasquau-Liano J, Jimenez-Morales A, Hidalgo-Tenorio C. Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections. *Sci Rep* **2022**; 12(1): 15261.
249. Shields RK, Anand R, Clarke LG, et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. *PLoS One* **2017**; 12(3): e0173286.
250. Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S. Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury. *Clin J Am Soc Nephrol* **2018**; 13(4): 542–50.
251. Kaase M, Szabados F, Anders A, Gatermann SG. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. *J Clin Microbiol* **2014**; 52(6): 1893–7.
252. Falagas ME, Romanos LT, Katritsi ED, Tzvetanova ID. Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies. *Int J Antimicrob Agents* **2026**; 67(4): 107723.
253. Emeraud C, Godmer A, Girlich D, et al. Activity of mecillinam against carbapenem-resistant Enterobacterales. *J Antimicrob Chemother* **2022**; 77(10): 2835–9.
254. Fuchs F, Ahmadzada A, Plambeck L, Wille T, Hamprecht A. Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam. *Front Microbiol* **2020**; 11: 627267.
255. Zykov IN, Frimodt-Moller N, Smabrekke L, Sundsfjord A, Samuelsen O. Efficacy of mecillinam against clinical multidrug-resistant *Escherichia coli* in a murine urinary tract infection model. *Int J Antimicrob Agents* **2020**; 55(2): 105851.
256. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. *Clin Infect Dis* **2016**; 63(6): 754–62.

257. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. *JAMA* **2018**; 319(8): 788–99.
258. Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* **2018**; 18(12): 1319–28.
259. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis* **2021**; 21(2): 226–40.
260. Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Castanheira M. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). *Eur J Clin Microbiol Infect Dis* **2022**; 41(3): 477–87.
261. Sader HS, Kimbrough JH, Winkler ML, Castanheira M, Mendes RE. Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). *J Antimicrob Chemother* **2025**; 80(8): 2070–9.
262. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. *J Antimicrob Chemother* **2017**; 72(9): 2616–26.
263. Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. *Int J Antimicrob Agents* **2016**; 47(4): 269–85.
264. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. *Curr Drug Metab* **2009**; 10(1): 13–21.
265. Zhou C, Jin L, Wang Q, et al. Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study. *Infect Drug Resist* **2021**; 14: 731–42.
266. Adelman MW, Bower CW, Grass JE, et al. Distinctive Features of Ertapenem-Mono-Resistant Carbapenem-Resistant Enterobacterales in the United States: A Cohort Study. *Open Forum Infect Dis* **2022**; 9(1): ofab643.
267. Shropshire WC, Amiji H, Bremer J, et al. Genetic determinants underlying the progressive phenotype of beta-lactam/beta-lactamase inhibitor resistance in *Escherichia coli*. *Microbiol Spectr* **2023**; 11(6): e0222123.
268. Shortridge D, Deshpande LM, Streit JM, Castanheira M. Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe. *JAC Antimicrob Resist* **2022**; 4(5): dlac097.

269. Bonnin RA, Bernabeu S, Emeraud C, et al. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales. *Antibiotics (Basel)* **2023**; 12(1).
270. Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, Poirel L. Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone beta-lactamase inhibitors against broad-spectrum AmpC beta-lactamases. *Antimicrob Agents Chemother* **2024**; 68(11): e0077524.
271. Chen J, Hu Q, Zhou P, Deng S. Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. *Infection* **2024**; 52(1): 19–28.
272. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant *Klebsiella pneumoniae* Bacteremia. *Antimicrob Agents Chemother* **2017**; 61(8).
273. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. *Infect Dis Ther* **2018**; 7(4): 439–55.
274. Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. *Clin Infect Dis* **2020**; 70(9): 1799–808.
275. van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. *Clin Infect Dis* **2018**; 66(2): 163–71.
276. Sader HS, Mendes RE, Duncan L, Kimbrough JH, Carvalhaes CG, Castanheira M. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022). *Diagn Microbiol Infect Dis* **2023**; 106(2): 115945.
277. Marino A, Maraolo AE, Mazzitelli M, et al. Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing *K. pneumoniae* infections- results from a retrospective multicentre study. *Infection* **2025**; 53(6): 2645–58.
278. Karaba SM, Hareza DA, Munita JM, Martinez JRW, Bergman Y, Hawes AM, Bulman ZP, Cosgrove SE, Simner PJ, Tamma PD. Comparative Outcomes of Ceftazidime-Avibactam versus Meropenem-Vaborbactam for KPC-producing Enterobacterales Infections. *Antimicrobial Agents and Chemotherapy*, 2025. Accepted for publication.
279. Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections. *Antimicrob Agents Chemother* **2020**; 64(5).

280. Leanza C, Mascellino MT, Volpicelli L, et al. Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing *Klebsiella pneumoniae* complex and difficult-to-treat resistance (DTR) *Pseudomonas aeruginosa* infections: a single-center preliminary experience. *Front Microbiol* **2024**; 15: 1432296.
281. Papp-Wallace KM, Barnes MD, Alsop J, et al. Relebactam Is a Potent Inhibitor of the KPC-2 beta-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. *Antimicrob Agents Chemother* **2018**; 62(6).
282. Papp-Wallace KM, Mack AR, Taracila MA, Bonomo RA. Resistance to Novel beta-Lactam-beta-Lactamase Inhibitor Combinations: The "Price of Progress". *Infect Dis Clin North Am* **2020**; 34(4): 773–819.
283. Shields RK, Potoski BA, Haidar G, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. *Clin Infect Dis* **2016**; 63(12): 1615–8.
284. Caston JJ, Gallo M, Garcia M, et al. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing *Klebsiella pneumoniae*: factors associated with clinical efficacy in a single-center cohort. *Int J Antimicrob Agents* **2020**; 56(3): 106075.
285. Tumbarello M, Raffaelli F, Giannella M, et al. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. *Open Forum Infect Dis* **2024**; 11(6): ofae273.
286. Di Bella S, Giacobbe DR, Maraolo AE, et al. Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. *J Glob Antimicrob Resist* **2021**; 25: 268–81.
287. Hobson CA, Pierrat G, Tenaillon O, et al. *Klebsiella pneumoniae* Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview. *Antimicrob Agents Chemother* **2022**; 66(9): e0044722.
288. Hamza M, Traglia GM, Maccari L, et al. Emerging Resistance to Novel beta-Lactam beta-Lactamase Inhibitor Combinations in *Klebsiella pneumoniae* bearing KPC Variants. *bioRxiv* **2025**.
289. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of *Escherichia coli* containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. *J Antimicrob Chemother* **2015**; 70(8): 2279–86.
290. Livermore DM, Warner M, Jamroz D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. *Antimicrob Agents Chemother* **2015**; 59(9): 5324–30.
291. Shields RK, Chen L, Cheng S, et al. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla(KPC-3) Mutations during Treatment of Carbapenem-Resistant *Klebsiella pneumoniae* Infections. *Antimicrob Agents Chemother* **2017**; 61(3).

292. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **2017**; 61(12).
293. Findlay J, Rens C, Poirel L, Nordmann P. In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **2022**; 66(10): e0091822.
294. Shields RK, McCreary EK, Marini RV, et al. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. *Clin Infect Dis* **2020**; 71(3): 667–71.
295. Wilson WR, Kline EG, Jones CE, et al. Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. *Antimicrob Agents Chemother* **2019**; 63(3).
296. Balabanian G, Rose M, Manning N, Landman D, Quale J. Effect of Porins and bla(KPC) Expression on Activity of Imipenem with Relebactam in *Klebsiella pneumoniae*: Can Antibiotic Combinations Overcome Resistance? *Microb Drug Resist* **2018**; 24(7): 877–81.
297. Gaibani P, Bovo F, Bussini L, et al. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing *Klebsiella pneumoniae* from a single patient during ceftazidime/avibactam-based treatments. *J Antimicrob Chemother* **2022**; 77(6): 1570–7.
298. Yasmin M, Marshall SH, Chen L, et al. A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **2024**; 68(10): e0020824.
299. Wise MG, Karlowsky JA, Mohamed N, Kamat S, Sahm DF. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021. *Eur J Clin Microbiol Infect Dis* **2023**; 42(9): 1135–43.
300. Wise MG, Karlowsky JA, Hackel MA, et al. In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined beta-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019. *Microb Drug Resist* **2023**; 29(8): 360–70.
301. Papp-Wallace KM, Sader HS, Maher JM, Kimbrough JH, Castanheira M. Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017–2022). *Open Forum Infect Dis* **2025**; 12(5): ofaf250.
302. Carmeli Y, Cisneros JM, Paul M, et al. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. *Lancet Infect Dis* **2025**; 25(2): 218–30.
303. Marshall S, Hujer AM, Rojas LJ, et al. Can Ceftazidime-Avibactam and Aztreonam Overcome beta-Lactam Resistance Conferred by Metallo-beta-Lactamases in Enterobacteriaceae? *Antimicrob Agents Chemother* **2017**; 61(4).

304. Deshpande LM, Doyle TB, Sader HS, Castanheira M. Activity of aztreonam-avibactam and ceftazidime-avibactam against beta-lactamase-producing enterobacterales Isolates from United States hospitals. *J Glob Antimicrob Resist* **2025**; 44: 103–10.
305. Sader HS, Kimbrough JH, Mendes RE, Castanheira M. Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales. *BMC Infect Dis* **2024**; 24(1): 1242.
306. Castanheira M, Kimbrough JH, Morgan GM, Karr M, Sader HS. Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-beta-lactamase-producing Enterobacterales. *Antimicrob Agents Chemother* **2026**; 70(1): e0084225.
307. Crandon JL, Nicolau DP. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-beta-lactamase producers. *Antimicrob Agents Chemother* **2013**; 57(7): 3299–306.
308. Das S, Riccobene T, Carrothers TJ, et al. Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. *Eur J Clin Pharmacol* **2024**; 80(4): 529–43.
309. Xie R, Rogers H, Chow JW, Soto E, Raber SR. Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. *Antimicrob Agents Chemother* **2025**; 69(8): e0195024.
310. Daikos GL, Cisneros JM, Carmeli Y, et al. Aztreonam-avibactam for the treatment of serious infections caused by metallo-beta-lactamase-producing Gram-negative pathogens: a Phase 3 randomized trial (ASSEMBLE). *JAC Antimicrob Resist* **2025**; 7(4): dlaf131.
311. Tamma PD, Lodise TP, Mojica MF, Perez F, Bonomo RA. Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam. *Clin Infect Dis* **2025**; 81(4): e241–e2.
312. Falcone M, Daikos GL, Tiseo G, et al. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales. *Clin Infect Dis* **2021**; 72(11): 1871–8.
313. Falcone M, Giordano C, Leonildi A, et al. Clinical Features and Outcomes of Infections Caused by Metallo-beta-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area. *Clin Infect Dis* **2024**; 78(5): 1111–9.
314. Harris H, Tao L, Jacobs EB, et al. Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test. *J Clin Microbiol* **2023**; 61(5): e0164722.
315. Lodise TP, Smith NM, O'Donnell N, et al. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. *J Antimicrob Chemother* **2020**; 75(9): 2622–32.

316. Falcone M, Menichetti F, Cattaneo D, et al. Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. *J Antimicrob Chemother* **2021**; 76(4): 1025–31.
317. Lodise TP, O'Donnell JN, Raja S, et al. Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers. *Antimicrob Agents Chemother* **2022**; 66(12): e0093522.
318. Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the Optimal Treatment for Metallo- and Serine-beta-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam. *Antimicrob Agents Chemother* **2019**; 63(12).
319. Biagi M, Lee M, Wu T, et al. Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-beta-lactamase-producing enterobacterales. *Diagn Microbiol Infect Dis* **2022**; 103(2): 115674.
320. Belati A, Bavaro DF, Diella L, De Gennaro N, Di Gennaro F, Saracino A. Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant *Klebsiella pneumoniae*: A Retrospective Case Series and Literature Review. *Antibiotics (Basel)* **2022**; 11(3).
321. Ito A, Sato T, Ota M, et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. *Antimicrob Agents Chemother* **2018**; 62(1).
322. Karakostas S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia*: a systematic review and meta-analysis. *Clin Microbiol Infect* **2024**; 30(2): 178–88.
323. Kimbrough JH, Maher JM, Sader HS, Castanheira M, Mendes RE. In vitro activity assessment of cefiderocol against Enterobacterales, *Pseudomonas aeruginosa*, and *Acinetobacter* spp., including beta-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals. *Microbiol Spectr* **2024**; 12(11): e0147424.
324. Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies. *Clin Infect Dis* **2022**; 75(6): 1081–4.
325. Paterson DL, Sulaiman H, Liu PY, et al. Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial. *Lancet Infect Dis* **2026**; 26(2): 148–59.
326. Sadek M, Juhas M, Poirer L, Nordmann P. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-beta-Lactamase-Producing *Escherichia coli* Isolates. *Antimicrob Agents Chemother* **2020**; 64(12).

327. Helsens N, Sadek M, Le Terrier C, Poirel L, Nordmann P. Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type beta-lactamases in PBP3-modified *Escherichia coli*. *Eur J Clin Microbiol Infect Dis* **2024**.
328. Livermore DM, Mushtaq S, Vickers A, Woodford N. Activity of aztreonam/avibactam against metallo-beta-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 beta-lactamase in *Escherichia coli*. *Int J Antimicrob Agents* **2023**; 61(5): 106776.
329. Long H, Zhao F, Feng Y, Zong Z. Global distribution of bla(CMY-42), a gene mediating reduced susceptibility to aztreonam-avibactam and ceftazidime-avibactam, in *Escherichia coli*. *Int J Antimicrob Agents* **2024**; 63(5): 107141.
330. Simner PJ, Bergman Y, Conzemius R, et al. An NDM-Producing *Escherichia coli* Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-beta-Lactam Resistance. *Open Forum Infect Dis* **2023**; 10(7): ofad276.
331. Eklund E, Maruca T, Kruczynski K, et al. High in vitro activity of aztreonam/avibactam against NDM-producing Enterobacterales with emerging resistance in *Escherichia coli* in the United States Mid-Atlantic region. *Microbiol Spectr* **2026**: e0397125.
332. Mushtaq S, Vickers A, Ellaby N, Woodford N, Livermore DM. Selection and characterization of mutational resistance to aztreonam/avibactam in beta-lactamase-producing Enterobacterales. *J Antimicrob Chemother* **2021**; 77(1): 98–111.
333. Niu S, Wei J, Zou C, et al. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing *Klebsiella pneumoniae*. *J Antimicrob Chemother* **2020**; 75(3): 559–65.
334. Karakostas S, Rousaki M, Kritsotakis EI. Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. *Antibiotics (Basel)* **2022**; 11(6).
335. Lan P, Lu Y, Chen Z, et al. Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant *Klebsiella pneumoniae* from Bloodstream Infections in Patients with Hematologic Malignancies in China. *Microbiol Spectr* **2022**; 10(2): e0008422.
336. McElheny CL, Fowler EL, Iovleva A, Shields RK, Doi Y. In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing *Klebsiella pneumoniae* Due to Functional Loss of CirA. *Microbiol Spectr* **2021**; 9(3): e0177921.
337. Simner PJ, Beisken S, Bergman Y, Ante M, Posch AE, Tamma PD. Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales. *Microb Drug Resist* **2022**; 28(2): 161–70.
338. Frohlich C, Sorum V, Tokuriki N, Johnsen PJ, Samuelsen O. Evolution of beta-lactamase-mediated cefiderocol resistance. *J Antimicrob Chemother* **2022**; 77(9): 2429–36.
339. Simner PJ, Mostafa HH, Bergman Y, et al. Progressive Development of Cefiderocol Resistance in *Escherichia coli* During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression. *Clin Infect Dis* **2022**; 75(1): 47–54.

340. Castanheira M, Doyle TB, Collingsworth TD, Sader HS, Mendes RE. Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. *J Antimicrob Chemother* **2021**; 76(12): 3125–34.
341. Sader HS, Carvalhaes CG, Kimbrough JH, Mendes RE, Castanheira M. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022). *Int J Antimicrob Agents* **2024**; 63(4): 107113.
342. Alqahtani H, Alghamdi A, Alobaidallah N, et al. Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy. *JAC Antimicrob Resist* **2022**; 4(5): dlac104.
343. Lima O, Sousa A, Longueira-Suarez R, et al. Ceftazidime-avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing *Klebsiella pneumoniae*. *Eur J Clin Microbiol Infect Dis* **2022**; 41(9): 1173–82.
344. Canver MC, Satlin MJ, Westblade LF, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. *Antimicrob Agents Chemother* **2019**; 63(9).
345. Asempa TE, Kois AK, Gill CM, Nicolau DP. Phenotypes, genotypes and breakpoints: an assessment of beta-lactam/beta-lactamase inhibitor combinations against OXA-48. *J Antimicrob Chemother* **2023**; 78(3): 636–45.
346. Outeda-Garcia M, Arca-Suarez J, Lence E, et al. Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors. *Antimicrob Agents Chemother* **2025**; 69(2): e0161424.
347. Bonnin RA, Bernabeu S, Emeraud C, et al. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam. *Int J Antimicrob Agents* **2022**; 60(4): 106660.
348. Blanco-Martin T, Guzman-Puche J, Hernandez-Garcia M, et al. Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from *Klebsiella pneumoniae* producing OXA-48-like enzymes. *J Antimicrob Chemother* **2025**; 80(12): 3265–72.
349. Frohlich C, Sorum V, Thomassen AM, Johnsen PJ, Leiros HS, Samuelsen O. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs. *mSphere* **2019**; 4(2).
350. Longshaw C, Roger E, Santerre Henriksen A, Baba T, Nguyen S, Yamano Y. Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials. *Antimicrob Agents Chemother* **2022**; 66(10): e0110022.
351. Garcia P, Guijarro-Sanchez P, Lasarte-Monterrubio C, et al. Activity and resistance mechanisms of the third generation tetracyclines tigecycline, eravacycline and omadacycline against nationwide Spanish

collections of carbapenemase-producing Enterobacterales and Acinetobacter baumannii. Biomed Pharmacother **2024**; 181: 117666.

352. Ni W, Han Y, Liu J, et al. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis. Medicine (Baltimore) **2016**; 95(11): e3126.
353. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Adv Ther **2020**; 37(3): 1049–64.
354. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care **2014**; 18(3): R90.
355. Karampatakis T, Tsergouli K, Lowrie K. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. Microb Pathog **2023**; 179: 106090.
356. United States Food and Drug Administration. Antibacterial Susceptibility Test Interpretive Criteria. <https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria>. Accessed December 31, 2025.
357. Amann LF, Broeker A, Riedner M, et al. Pharmacokinetic/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella Pneumoniae isolates. Diagn Microbiol Infect Dis **2024**; 108(2): 116153.
358. Solomkin J, Evans D, Slepavicius A, et al. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial. JAMA Surg **2017**; 152(3): 224–32.
359. Solomkin JS, Gardovskis J, Lawrence K, et al. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections. Clin Infect Dis **2019**; 69(6): 921–9.
360. Patino K, Vathy R, Albrecht B, Suchindran S, Green SB. Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections. Microbiol Spectr **2025**; 13(12): e0131425.
361. Wang Z, Gan G, Yao H. Gastrointestinal risk profile of tigecycline, omadacycline and eravacycline: Evidence from the FDA adverse event reporting system. Acta Pharm **2025**.
362. Chen A, Smith KP, Whitfield BA, et al. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline. Diagn Microbiol Infect Dis **2017**; 88(4): 365–7.
363. Crowley PD, Ranganath N, Mira P, et al. Show Me the "Mino:" In Vitro Efficacy of Minocycline on Clinical Gram-Negative Bacterial Isolates. Microb Drug Resist **2026**: 10766294261424485.

364. Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. *Clin Infect Dis* **2014**; 59 Suppl 6: S388–93.
365. Mirza HC, Guclu AU, Ince Ceviz G, Basustaoglu A. Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of *K. pneumoniae*. *J Med Microbiol* **2022**; 71(10).
366. Lee YL, Ko WC, Lee WS, et al. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. *Int J Antimicrob Agents* **2021**; 58(3): 106377.
367. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. *Clin Microbiol Rev* **2012**; 25(3): 450–70.
368. Perez-Nadales E, Fernandez-Ruiz M, Natera AM, et al. Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing *Klebsiella pneumoniae*. *Am J Transplant* **2023**; 23(7): 1022–34.
369. Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-Avibactam Use for *Klebsiella pneumoniae* Carbapenemase-Producing *K. pneumoniae* Infections: A Retrospective Observational Multicenter Study. *Clin Infect Dis* **2021**; 73(9): 1664–76.
370. Meschiari M, Faltoni M, Kaleci S, et al. Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience. *Int J Antimicrob Agents* **2024**; 63(5): 107134.
371. Anastasia A, Bonura S, Rubino R, et al. The Use of Intravenous Fosfomycin in Clinical Practice: A 5-Year Retrospective Study in a Tertiary Hospital in Italy. *Antibiotics (Basel)* **2023**; 12(6).
372. Onal U, Tuzemen U, Kucukdemirci Kaya P, et al. A comparative study of ceftazidime/avibactam-based and fosfomycin plus meropenem-based regimens for managing infections caused by carbapenem-resistant *Klebsiella pneumoniae* in critically ill patients. *J Chemother* **2025**; 37(1): 1–9.
373. Belati A, Diella L, Bavaro DF, et al. Intravenous Fosfomycin as Adjunctive Therapy for Gram-Negative Bacteria Bloodstream Infections: A Propensity Score Adjusted Retrospective Cohort Study. *Int J Antimicrob Agents* **2024**; 64(2): 107247.
374. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* **2012**; 18(3): 268–81.
375. Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clin Infect Dis* **2018**; 67(12): 1803–14.

376. Oliver A, Arca-Suarez J, Gomis-Font MA, Gonzalez-Pinto L, Lopez-Causape C. Emerging resistance mechanisms to newer beta-lactams in *Pseudomonas aeruginosa*. *Clin Microbiol Infect* **2025**.
377. Tekes-Manuva D, Babich T, Kozlovski D, et al. What is the most effective antibiotic monotherapy for severe *Pseudomonas aeruginosa* infection? A systematic review and meta-analysis of randomized controlled trials. *Clin Microbiol Infect* **2025**; 31(5): 740–52.
378. Babich T, Naucler P, Valik JK, et al. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite Retrospective Study. *Clin Infect Dis* **2020**; 70(11): 2270–80.
379. European Committee on Antimicrobial Susceptibility Testing.
<https://www.eucast.org/bacteria/clinical-breakpoints-and-interpretation/clinical-breakpoint-tables/>. Accessed December 31, 2025.
380. Tamma PD, Harris PNA, Mathers AJ, Wenzler E, Humphries RM. Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against *Pseudomonas aeruginosa*. *Clin Infect Dis* **2023**; 76(10): 1868–70.
381. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against *Pseudomonas aeruginosa*. *Pharmacotherapy* **2003**; 23(3): 291–5.
382. Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. *Int J Antimicrob Agents* **2011**; 37(1): 46–50.
383. Reeder JA, Creech CB, Nation RL, et al. Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients. *J Clin Pharmacol* **2025**; 65(4): 452–65.
384. Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with *Pseudomonas aeruginosa* infections. *Antimicrob Agents Chemother* **2013**; 57(7): 2907–12.
385. Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for *Pseudomonas aeruginosa* infection: clinical implications of an extended-infusion dosing strategy. *Clin Infect Dis* **2007**; 44(3): 357–63.
386. Gill CM, Aktas E, Alfouzan W, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant *Pseudomonas aeruginosa*: Implications for Dose Optimization. *Antimicrob Agents Chemother* **2021**; 65(11): e0120421.
387. Reyes J, Komarow L, Chen L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort study. *Lancet Microbe* **2023**; 4(3): e159–e70.
388. Fuhs DT, Cortes-Lara S, Tait JR, et al. The effects of single and multiple resistance mechanisms on bacterial response to meropenem. *Clin Microbiol Infect* **2024**; 30(10): 1276–83.

389. Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of *Pseudomonas aeruginosa*. *J Bacteriol* **1993**; 175(24): 7793–800.
390. Supreeyasakon S, Traipattanakul J, Hemapanpairao J, Juntanawiwat P, Santimaleeworagun W. Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against *Pseudomonas aeruginosa* resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem beta-lactam agents. *PLoS One* **2024**; 19(11): e0313944.
391. Aldardeer NF, Labban HM, Alhuthil RT, et al. Effectiveness of traditional non-carbapenem beta-lactams vs. novel beta-lactams for the treatment of carbapenem-resistant *Pseudomonas aeruginosa*: a retrospective cohort study. *BMC Infect Dis* **2024**; 24(1): 1455.
392. Ng TH, Zhao JJ, Gumbleton R, Olson S, Smith S, Scipione MR. Treatment Outcomes for Carbapenem-Resistant and Cephalosporin-Susceptible *Pseudomonas aeruginosa* Pneumonia. *Ann Pharmacother* **2024**; 58(6): 581–8.
393. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet* **2015**; 385(9981): 1949–56.
394. Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. *Antimicrob Agents Chemother* **2018**; 62(8).
395. Sorli L, Luque S, Li J, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant *Pseudomonas aeruginosa*: Dose is critical. *J Infect* **2019**; 79(3): 253–61.
396. Titov I, Wunderink RG, Roquilly A, et al. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). *Clin Infect Dis* **2021**; 73(11): e4539–e48.
397. Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant *Pseudomonas aeruginosa*. *Clin Infect Dis* **2020**; 71(2): 304–10.
398. Long WM, Xu WX, Hu Q, et al. The efficacy and safety of ceftazidime/avibactam or polymyxin B based regimens for carbapenem-resistant *Pseudomonas aeruginosa* infection: a multicenter real-world and propensity score-matched study. *Front Pharmacol* **2025**; 16: 1533952.
399. Lodise TP, Min J, Nathanson BH, Yucel E. Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR *Pseudomonas aeruginosa* (PUMA). *Antimicrob Agents Chemother* **2025**; 69(11): e0056925.

400. Liu C, Leng B, Xie M, et al. Comparing ceftazidime/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: A propensity score-matched retrospective cohort study. *Int J Antimicrob Agents* **2025**; 65(3): 107418.
401. Almangour TA, Alkherb Z, Ghonem L, et al. Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Infections: A Multicenter Cohort Study. *Pharmaceuticals (Basel)* **2025**; 18(1).
402. Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant *Pseudomonas aeruginosa* Infections in the Compassionate Use Program. *Antimicrob Agents Chemother* **2023**; 67(7): e0019423.
403. Soueges S, Faure E, Parize P, et al. Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. *J Infect* **2025**; 90(1): 106376.
404. Lombardi A, Giacobbe DR, Mangioni D, et al. Cefiderocol therapy among immunocompromised adult patients: a descriptive analysis from a prospective, multicentre cohort study. *BMC Infect Dis* **2025**; 25(1): 1339.
405. Almangour TA, Ghonem L, Alassiri D, et al. Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant *Pseudomonas aeruginosa*: a Multicenter Cohort Study. *Antimicrob Agents Chemother* **2023**; 67(8): e0040523.
406. Hareza DA, Cosgrove SE, Bonomo RA, et al. Clinical outcomes and emergence of resistance of *Pseudomonas aeruginosa* infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam. *Antimicrob Agents Chemother* **2024**; 68(10): e0090724.
407. Shields RK, Abbo LM, Ackley R, et al. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the USA (CACTUS): a multicentre, retrospective, observational study. *Lancet Infect Dis* **2025**; 25(5): 574–84.
408. Lodise TP, Obi EN, Watanabe AH, Yucel E, Min J, Nathanson BH. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2024**; 79(11): 2954–64.
409. Caro L, Nicolau DP, De Waele JJ, et al. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. *J Antimicrob Chemother* **2020**; 75(6): 1546–53.
410. Nicolau DP, Siew L, Armstrong J, et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. *J Antimicrob Chemother* **2015**; 70(10): 2862–9.

411. Karlowsky JA, Lob SH, Bauer KA, et al. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates-SMART United States 2019-21. JAC Antimicrob Resist **2024**; 6(1): dlad152.
412. Gottesdiener LS, Li Y, Greenwood-Quaintance KE, et al. Resistance to novel β -lactam/ β -lactamase inhibitors among carbapenem-resistant *Pseudomonas aeruginosa* and clinical implications in the prospective observational *Pseudomonas* study. Antimicrob Agents Chemother . 2026 May 15:e0038825.
413. Wangchinda W, Wu JY, Abbo LM, et al. Effectiveness of imipenem-relebactam for multidrug-resistant *Pseudomonas aeruginosa* in pneumonia and bloodstream infections in the United States (MIRAGE). Antimicrob Agents Chemother **2025**; 69(12): e0132525.
414. Sabour S, Harrington KRV, Martinson E, et al. Characterization of carbapenem-resistant Enterobacterales and *Pseudomonas aeruginosa* carrying multiple carbapenemase genes-Antimicrobial Resistance Laboratory Network, 2018-2022. J Clin Microbiol **2024**; 62(12): e0122024.
415. M PE-V, Sola-Campoy PJ, Zurita AM, et al. Carbapenemase-producing *Pseudomonas aeruginosa* in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying bla(VIM-2), bla(VIM-1), bla(IMP-8), bla(VIM-20) and bla(KPC-2). Int J Antimicrob Agents **2020**; 56(1): 106026.
416. Koumaki V, Voudanta E, Michelaki A, et al. Epidemiological Trends of Carbapenemase-Producing *Pseudomonas aeruginosa* in a Tertiary Care Hospital in Athens, Greece, During 2020-2023. Antibiotics (Basel) **2025**; 14(9).
417. Ramatla T, Nkhebenyane J, Lekota KE, et al. Global prevalence and antibiotic resistance profiles of carbapenem-resistant *Pseudomonas aeruginosa* reported from 2014 to 2024: a systematic review and meta-analysis. Front Microbiol **2025**; 16: 1599070.
418. Gill CM, Aktathorn E, Alfouzan W, et al. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant *Pseudomonas aeruginosa*. Eur J Clin Microbiol Infect Dis **2021**; 40(12): 2533–41.
419. Morelli MK, Kloosterboer A, Fulton SA, et al. Investigating and Treating a Corneal Ulcer Due to Extensively Drug-Resistant *Pseudomonas aeruginosa*. Antimicrob Agents Chemother **2023**; 67(7): e0027723.
420. Sundermann AJ, Rangachar Srinivasa V, Mills EG, et al. Two Artificial Tears Outbreak-Associated Cases of Extensively Drug-Resistant *Pseudomonas aeruginosa* Detected Through Whole Genome Sequencing-Based Surveillance. J Infect Dis **2024**; 229(2): 517–21.
421. Grossman MK, Rankin DA, Maloney M, et al. Extensively Drug-Resistant *Pseudomonas aeruginosa* Outbreak Associated With Artificial Tears. Clin Infect Dis **2024**; 79(1): 6–14.

422. Khan A, Tran TT, Rios R, et al. Extensively Drug-Resistant *Pseudomonas aeruginosa* ST309 Harboring Tandem Guiana Extended Spectrum beta-Lactamase Enzymes: A Newly Emerging Threat in the United States. *Open Forum Infect Dis* **2019**; 6(7): ofz273.
423. Hishinuma T, Tada T, Kuwahara-Arai K, Yamamoto N, Shimojima M, Kirikae T. Spread of GES-5 carbapenemase-producing *Pseudomonas aeruginosa* clinical isolates in Japan due to clonal expansion of ST235. *PLoS One* **2018**; 13(11): e0207134.
424. Gill CM, Santini D, Nicolau DP, Group E-PGS. In vitro activity of cefiderocol against a global collection of carbapenem-resistant *Pseudomonas aeruginosa* with a high level of carbapenemase diversity. *J Antimicrob Chemother* **2024**; 79(2): 412–6.
425. Kirkegaard-Biosca C, Del Barrio-Tofino E, Villamarin M, et al. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. *Antibiotics (Basel)* **2024**; 13(9).
426. Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria. *Antimicrob Agents Chemother* **2020**; 64(12).
427. Kocer K, My TN, Sy BT, et al. Efficacy of cefiderocol in combination with xerubor-bactam versus tanibor-bactam against cefiderocol-resistant NDM-producing *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **2025**; 69(11): e0085725.
428. Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA. In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and *Pseudomonas aeruginosa* Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015. *Antimicrob Agents Chemother* **2017**; 61(9).
429. Le Terrier C, Nordmann P, Poirel L. In vitro activity of aztreonam in combination with newly developed beta-lactamase inhibitors against MDR Enterobacterales and *Pseudomonas aeruginosa* producing metallo-beta-lactamases. *J Antimicrob Chemother* **2022**; 78(1): 101–7.
430. Nakae T, Nakajima A, Ono T, Saito K, Yoneyama H. Resistance to beta-lactam antibiotics in *Pseudomonas aeruginosa* due to interplay between the MexAB-OprM efflux pump and beta-lactamase. *Antimicrob Agents Chemother* **1999**; 43(5): 1301–3.
431. Muller SE, Junker S, Rehner J, et al. Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2025**; 80(12): 3352–6.
432. Montero MM, Domene-Ochoa S, Prim N, et al. Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing *Pseudomonas aeruginosa*: insights from the hollow-fiber infection model. *Infect Dis (Lond)* **2025**; 57(1): 81–8.
433. Pina-Sanchez M, Rua M, Lopez-Causape C, et al. Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing *Pseudomonas aeruginosa* infections: good enough to have another? *J Antimicrob Chemother* **2025**; 80(5): 1371–6.

434. Vega AD, DeRonde K, Jimenez A, et al. Difficult-to-treat (DTR) *Pseudomonas aeruginosa* harboring Verona-Integron metallo-beta-lactamase (bla(VIM)): infection management and molecular analysis. *Antimicrob Agents Chemother* **2024**; 68(5): e0147423.
435. Sempere A, Vinado B, Los-Arcos I, et al. Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria. *Antimicrob Agents Chemother* **2022**; 66(10): e0075122.
436. Kimbrough JH, Karr MH, Nguyen ST, et al. Activity of cefiderocol against *Pseudomonas aeruginosa* from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed beta-lactam/beta-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. *Microbiol Spectr* **2025**; 13(11): e0207925.
437. Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF. In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019. *Antimicrob Agents Chemother* **2022**; 66(2): e0199021.
438. Tsai YV, Bookstaver PB, Kohn J, et al. The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel beta-lactam antibiotics in the southeastern United States. *Antimicrob Steward Healthc Epidemiol* **2024**; 4(1): e35.
439. Berrazeg M, Jeannot K, Ntsogo Enguene VY, et al. Mutations in beta-Lactamase AmpC Increase Resistance of *Pseudomonas aeruginosa* Isolates to Antipseudomonal Cephalosporins. *Antimicrob Agents Chemother* **2015**; 59(10): 6248–55.
440. Fraile-Ribot PA, Cabot G, Mulet X, et al. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2018**; 73(3): 658–63.
441. Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Infections: Clinical Effectiveness and Evolution of Resistance. *Clin Infect Dis* **2017**; 65(1): 110–20.
442. Rubio AM, Kline EG, Jones CE, et al. In Vitro Susceptibility of Multidrug-Resistant *Pseudomonas aeruginosa* following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. *Antimicrob Agents Chemother* **2021**; 65(6).
443. Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. *Clin Infect Dis* **2021**; 73(11): e4599–e606.
444. Nguyen HA, Peleg AY, Song J, et al. Complex pathways to ceftolozane-tazobactam resistance in clinical *Pseudomonas aeruginosa* isolates: a genomic epidemiology study. *Clin Microbiol Infect* **2026**; 32(1): 110–7.
445. Shah S, Kline EG, Haidar G, et al. Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant *Pseudomonas aeruginosa* Bacteremia or Pneumonia. *Clin Infect Dis* **2025**; 80(1): 24–8.

446. Gonzalez-Pinto L, Blanco-Martin T, Alonso-Garcia I, et al. Impact of transferable beta-lactamases and intrinsic AmpC amino acid substitutions on the activity of cefiderocol against wild-type and iron uptake-deficient mutants of *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2024**; 79(11): 3023–8.
447. Sastre-Femenia MA, Fernandez-Munoz A, Gomis-Font MA, et al. Spanish nationwide survey of *Pseudomonas aeruginosa* cefiderocol susceptibility and resistance mechanisms. *Int J Antimicrob Agents* **2025**; 66(4): 107563.
448. Shields RK, Kline EG, Squires KM, Van Tyne D, Doi Y. In vitro activity of cefiderocol against *Pseudomonas aeruginosa* demonstrating evolved resistance to novel beta-lactam/beta-lactamase inhibitors. *JAC Antimicrob Resist* **2023**; 5(5): dlad107.
449. Lopez-Causape C, Maruri-Aransolo A, Gomis-Font MA, et al. Cefiderocol resistance genomics in sequential chronic *Pseudomonas aeruginosa* isolates from cystic fibrosis patients. *Clin Microbiol Infect* **2023**; 29(4): 538 e7– e13.
450. Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD. Cefiderocol Activity Against Clinical *Pseudomonas aeruginosa* Isolates Exhibiting Ceftolozane-Tazobactam Resistance. *Open Forum Infect Dis* **2021**; 8(7): ofab311.
451. Gomis-Font MA, Cabot G, Sanchez-Diener I, et al. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in *Pseudomonas aeruginosa*. *J Antimicrob Chemother* **2020**; 75(9): 2508–15.
452. Gomis-Font MA, Cabot G, Lopez-Arguello S, et al. Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in *Pseudomonas aeruginosa* XDR high-risk clones. *J Antimicrob Chemother* **2022**; 77(4): 957–68.
453. Shields RK, Stellfox ME, Kline EG, Samanta P, Van Tyne D. Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant *Pseudomonas aeruginosa* Pneumonia. *Clin Infect Dis* **2022**; 75(4): 710–4.
454. Piccica M, Spinicci M, Botta A, et al. Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. *J Antimicrob Chemother* **2023**; 78(11): 2752–61.
455. Corbella L, Boan J, San-Juan R, et al. Effectiveness of ceftazidime-avibactam for the treatment of infections due to *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* **2022**; 59(2): 106517.
456. Giske CG, Amara M, Canton R, et al. Aminoglycoside breakpoints-the EUCAST approach and what this means for the clinician. *Clin Microbiol Infect* **2025**; 31(12): 1954–7.
457. Bhavnani SM, Hammel JP, Onufrak NJ, et al. Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and *Pseudomonas aeruginosa*. *Open Forum Infect Dis* **2025**; 12(12): ofaf426.

458. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. *Clin Infect Dis* **2013**; 57(9): 1300–3.
459. Phe K, Lee Y, McDanel PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. *Antimicrob Agents Chemother* **2014**; 58(5): 2740–6.
460. Rigatto MH, Oliveira MS, Perdigao-Neto LV, et al. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B. *Antimicrob Agents Chemother* **2016**; 60(4): 2443–9.
461. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwina N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. *J Antimicrob Chemother* **2010**; 65(12): 2645–9.
462. Kollef MH, Ricard JD, Roux D, et al. A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial. *Chest* **2017**; 151(6): 1239–46.
463. Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. *Lancet Infect Dis* **2020**; 20(3): 330–40.
464. Qin JP, Huang HB, Zhou H, Zhu Y, Xu Y, Du B. Amikacin nebulization for the adjunctive therapy of gram-negative pneumonia in mechanically ventilated patients: a systematic review and meta-analysis of randomized controlled trials. *Sci Rep* **2021**; 11(1): 6969.
465. Zhang Z, Li H, Hu Y, et al. The efficacy and safety of inhaled antibiotics for pneumonia: A systematic review and meta-analysis. *Pulm Pharmacol Ther* **2024**; 86: 102315.
466. Wu M, Yang X, Tian J, Fan H, Zhang Y. Antibiotic Treatment of Pulmonary Infections: An Umbrella Review and Evidence Map. *Front Pharmacol* **2021**; 12: 680178.
467. Sella N, Pettenuzzo T, De Cassai A, et al. Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis. *Crit Care* **2024**; 28(1): 387.
468. Boisson M, Jacobs M, Gregoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. *Antimicrob Agents Chemother* **2014**; 58(12): 7331–9.
469. Rouby JJ, Bouhemad B, Monsel A, et al. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. *Anesthesiology* **2012**; 117(6): 1364–80.
470. Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled Antibiotics for Gram-Negative Respiratory Infections. *Clin Microbiol Rev* **2016**; 29(3): 581–632.

471. Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E. A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia. *Antibiotics (Basel)* **2019**; 8(1).
472. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* **2016**; 63(5): e61–e111.
473. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy* **2019**; 39(1): 10–39.
474. Rello J, Sole-Lleonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect* **2017**; 23(9): 629–39.
475. Meschiari M, Asquier-Khati A, Tiseo G, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases. *Int J Antimicrob Agents* **2024**; 64(1): 107186.
476. Axiotakis LG, Jr., Enver N, Keating CL, Pitman MJ. Laryngeal Injury Due to Amikacin Inhalation for Refractory *Mycobacterium avium* Complex Infection. *Chest* **2021**; 159(4): e185–e7.
477. Niederman MS. Adjunctive Nebulized Antibiotics: What Is Their Place in ICU Infections? *Front Med (Lausanne)* **2019**; 6: 99.
478. Dubey V, Reza N, Hope W. Drug-resistant *Acinetobacter baumannii*: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. *Clin Microbiol Rev* **2025**; 38(3): e0027924.
479. Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important *Acinetobacter* spp.: an update. *Future Sci OA* **2019**; 5(6): FSO395.
480. Iovleva A, Mustapha MM, Griffith MP, et al. Carbapenem-Resistant *Acinetobacter baumannii* in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. *mBio* **2022**; 13(2): e0275921.
481. Mack AR, Hujer AM, Mojica MF, et al. beta-Lactamase diversity in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2025**; 69(3): e0078424.
482. Valcek A, Nesporova K, Whiteway C, et al. Genomic Analysis of a Strain Collection Containing Multidrug-, Extensively Drug-, Pandrug-, and Carbapenem-Resistant Modern Clinical Isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2022**; 66(9): e0089222.
483. Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS Microbiol Lett* **2006**; 258(1): 72–7.

484. Takebayashi Y, Findlay J, Heesom KJ, Warburton PJ, Avison MB, Evans BA. Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) beta-lactamase enzymes in *Acinetobacter baumannii*. *J Antimicrob Chemother* **2021**; 76(3): 587–95.
485. Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European *Acinetobacter baumannii* clones. *J Med Microbiol* **2004**; 53(Pt 12): 1233–40.
486. Catel-Ferreira M, Coadou G, Molle V, et al. Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of *Acinetobacter baumannii*. *J Antimicrob Chemother* **2011**; 66(9): 2053–6.
487. Snyder DS, McIntosh TJ. The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics. *Biochemistry* **2000**; 39(38): 11777–87.
488. Yoon EJ, Chabane YN, Goussard S, et al. Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in *Acinetobacter baumannii*. *mBio* **2015**; 6(2).
489. Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2015**; 59(3): 1680–9.
490. McLeod SM, Shapiro AB, Moussa SH, et al. Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel beta-Lactamase Inhibitor ETX2514 in Clinical Isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2018**; 62(2).
491. Seward RJ, Towner KJ. Molecular epidemiology of quinolone resistance in *Acinetobacter* spp. *Clin Microbiol Infect* **1998**; 4(5): 248–54.
492. Williams JD. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. *Clin Infect Dis* **1997**; 24(3): 494–7.
493. Barnes MD, Kumar V, Bethel CR, et al. Targeting Multidrug-Resistant *Acinetobacter* spp.: Sulbactam and the Diazabicyclooctenone beta-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. *mBio* **2019**; 10(2).
494. Palavecino EL, Kilic A. In vitro activity of cefiderocol and sulbactam-durlobactam against carbapenem-resistant *Acinetobacter baumannii* clinical isolates collected between 2019 and 2024. *Infect Dis (Lond)* **2025**: 1–6.
495. Buyukyanbolu E, Argotsinger J, Beck ET, et al. Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against *Acinetobacter baumannii*-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study. *Antimicrob Agents Chemother* **2025**; 69(8): e0037925.

496. Wang M, Ge L, Chen L, et al. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant *Acinetobacter baumannii* Among Patients From Different Global Regions. *Clin Infect Dis* **2024**; 78(2): 248–58.
497. Saikia S, Gogoi I, Oloo A, Sharma M, Puzari M, Chetia P. Co-production of metallo-beta-lactamase and OXA-type beta-lactamases in carbapenem-resistant *Acinetobacter baumannii* clinical isolates in North East India. *World J Microbiol Biotechnol* **2024**; 40(6): 167.
498. Amar AK, Panda L, Prasad K, et al. Increasing Burden of Antibiotic Resistance in India Due to Co-existence of Multiple Classes of Carbapenem and Different Aminoglycoside Resistance Genes in Clinical Isolates of *Acinetobacter baumannii*. *Curr Microbiol* **2025**; 82(3): 120.
499. AlAmri AM, AlQurayan AM, Sebastian T, AlNimr AM. Molecular Surveillance of Multidrug-Resistant *Acinetobacter baumannii*. *Curr Microbiol* **2020**; 77(3): 335–42.
500. Singh S, Verma A, Venkatesh V, Verma S, Reddy DH, Agrawal A. The Clinical Impression of NDM-producing *Acinetobacter baumannii* in Intensive Care Units of the University Referral Hospital in North India. *Indian J Crit Care Med* **2024**; 28(11): 1044–9.
501. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by *Acinetobacter baumannii*-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). *Lancet Infect Dis* **2023**; 23(9): 1072–84.
502. Shields RK, Paterson DL, Tamma PD. Navigating Available Treatment Options for Carbapenem-Resistant *Acinetobacter baumannii*-calcoaceticus Complex Infections. *Clin Infect Dis* **2023**; 76(Suppl 2): S179–S93.
503. Tanudra A, McLeod S, Miller A, Tommasi R, O'Donnell J. Sulbactam-durlobactam (SUL-DUR) in vitro dose response studies with and without imipenem or meropenem carbapenemase-producing *Acinetobacter baumannii* utilizing the hollow-fiber infection model. ECCMID 2022, Lisbon, Portugal, Poster 02037.
504. Choi JY, Park YS, Cho CH, et al. Synergic in-vitro activity of imipenem and sulbactam against *Acinetobacter baumannii*. *Clin Microbiol Infect* **2004**; 10(12): 1098–101.
505. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of *Acinetobacter baumannii*. *J Antimicrob Chemother* **2003**; 51(3): 565–74.
506. Veeraraghavan B, Shin E, Bakthavatchalam YD, et al. A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of *Acinetobacter* spp. *Antimicrob Agents Chemother* **2025**; 69(4): e0162724.
507. O'Donnell J, Tanudra A, Chen A, Miller AA, McLeod SM, Tommasi R. In vitro pharmacokinetics/pharmacodynamics of the beta-lactamase inhibitor, durlobactam, in combination with sulbactam against *Acinetobacter baumannii*-calcoaceticus complex. *Antimicrob Agents Chemother* **2024**; 68(1): e0031223.

508. Moussa SH, Shapiro AB, McLeod SM, et al. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2023**; 67(11): e0066523.
509. Bianco G, Biffignandi GB, Boattini M, et al. Resistance to sulbactam/durlobactam in carbapenem-resistant *Acinetobacter baumannii* in treatment-naïve setting: in vitro data and genomic insights from Italian bloodstream isolates. *Int J Antimicrob Agents* **2026**: 107718.
510. Xu Q, Liu X, Liu H, et al. In vitro activity and resistance mechanisms of sulbactam/durlobactam against *Acinetobacter baumannii* clinical isolates in China (2019-2020). *Clin Microbiol Infect* **2026**; 32(1): 102–9.
511. Halim J, Keane AP, Bouzo J, et al. Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant *Acinetobacter baumannii* patient isolates with diverse resistance mechanisms. *J Antimicrob Chemother* **2025**; 80(10): 2814–24.
512. Noguchi JK, Gill MA. Sulbactam: a beta-lactamase inhibitor. *Clin Pharm* **1988**; 7(1): 37–51.
513. Lenhard JR, Smith NM, Bulman ZP, et al. High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant *Acinetobacter baumannii* in a Hollow-Fiber Infection Model. *Antimicrob Agents Chemother* **2017**; 61(3).
514. Beganovic M, Daffinee KE, Luther MK, LaPlante KL. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant *Acinetobacter baumannii* in an In Vitro Pharmacodynamic Model. *Antimicrob Agents Chemother* **2021**; 65(3).
515. Abdul-Mutakabbir JC, Yim J, Nguyen L, et al. In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant *Acinetobacter baumannii*. *Antibiotics (Basel)* **2021**; 10(7).
516. Rodriguez-Hernandez MJ, Cuberos L, Pichardo C, et al. Sulbactam efficacy in experimental models caused by susceptible and intermediate *Acinetobacter baumannii* strains. *J Antimicrob Chemother* **2001**; 47(4): 479–82.
517. Abouelhassan Y, Kuti JL, Nicolau DP, Abdelraouf K. Ampicillin-sulbactam against *Acinetobacter baumannii* infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations. *J Antimicrob Chemother* **2024**; 79(9): 2227–36.
518. Abouelhassan Y, Nicolau DP, Abdelraouf K. Defining optimal sulbactam regimens for treatment of *Acinetobacter baumannii* pneumonia and impact of blaOXA-23 on efficacy. *J Antimicrob Chemother* **2024**; 79(9): 2306–16.
519. Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant *Acinetobacter baumannii* infections: A systematic review and network meta-analysis. *J Glob Antimicrob Resist* **2021**; 24: 136–47.

520. Jung SY, Lee SH, Lee SY, et al. Antimicrobials for the treatment of drug-resistant *Acinetobacter baumannii* pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. *Crit Care* **2017**; 21(1): 319.
521. SENTRY Antimicrobial Surveillance Program. JMI laboratories; 2025. <https://sentry-mvp.jmilabs.com>. Accessed December 31, 2025.
522. Pfizer ATLAS Antimicrobial Testing Leadership and Surveillance; 2025. <https://atlas-surveillance.com/login>. Accessed December 31, 2025.
523. Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakittrangsarn M. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by *Acinetobacter baumannii*. *Eur J Pharm Sci* **2019**; 136: 104940.
524. Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, et al. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2016**; 60(12): 7236–44.
525. Fernandez-Cuenca F, Tomas M, Caballero-Moyano FJ, et al. Reporting antimicrobial susceptibilities and resistance phenotypes in *Acinetobacter* spp: a nationwide proficiency study. *J Antimicrob Chemother* **2018**; 73(3): 692–7.
526. Viana GF, Saalfeld SM, Moreira RR, et al. Can ampicillin/sulbactam resistance in *Acinetobacter baumannii* be predicted accurately by disk diffusion? *J Glob Antimicrob Resist* **2013**; 1(4): 221–3.
527. Khalili H, Shojaei L, Mohammadi M, Beigmohammadi MT, Abdollahi A, Doomanlou M. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia. *J Comp Eff Res* **2018**; 7(9): 901–11.
528. Pourheidar E, Haghighi M, Koucheh M, et al. Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug Resistant *Acinetobacter Baumannii*: Randomized Open Label Trial. *Iran J Pharm Res* **2019**; 18(Suppl1): 269–81.
529. Makris D, Petinaki E, Tsolaki V, et al. Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant *Acinetobacter baumannii* Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study. *Indian J Crit Care Med* **2018**; 22(2): 67–77.
530. Mosaed R, Haghighi M, Kouchak M, et al. Interim Study: Comparison Of Safety And Efficacy of Levofloxacin Plus Colistin Regimen With Levofloxacin Plus High Dose Ampicillin/Sulbactam Infusion In Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant *Acinetobacter*. *Iran J Pharm Res* **2018**; 17(Suppl2): 206–13.

531. Asrat H, Samaroo-Campbell J, Ata S, Quale J. Contribution of Iron-Transport Systems and beta-Lactamases to Cefiderocol Resistance in Clinical Isolates of *Acinetobacter baumannii* Endemic to New York City. *Antimicrob Agents Chemother* **2023**; 67(6): e0023423.
532. Smoke SM, Brophy A, Reveron S, et al. Evolution and Transmission of Cefiderocol-Resistant *Acinetobacter baumannii* During an Outbreak in the Burn Intensive Care Unit. *Clin Infect Dis* **2023**; 76(3): e1261–e5.
533. Raro OHF, Findlay J, Poirel L, Decousser JW, Nordmann P. In vitro selection of cefiderocol-resistant mutants in *Acinetobacter baumannii* harbouring the most common carbapenemase genes. *J Antimicrob Chemother* **2026**; 81(1).
534. Poirel L, Sadek M, Nordmann P. Contribution of PER-Type and NDM-Type beta-Lactamases to Cefiderocol Resistance in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2021**; 65(10): e0087721.
535. Nakamura R, Ito-Horiyama T, Takemura M, et al. In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models. *Antimicrob Agents Chemother* **2019**; 63(9).
536. Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. *Antimicrob Agents Chemother* **2017**; 61(11).
537. Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP. Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. *Antimicrob Agents Chemother* **2019**; 63(2).
538. Matsumoto S, Singley CM, Hoover J, et al. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics. *Antimicrob Agents Chemother* **2017**; 61(9).
539. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis* **2021**; 21(2): 213–25.
540. Onorato L, de Luca I, Monari C, Coppola N. Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant *Acinetobacter baumannii* infections: A systematic review and meta-analysis. *J Infect* **2024**; 88(3): 106113.
541. Zhan Y, Mao W, Zhao C, et al. Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant *Acinetobacter baumannii*: a systematic review with meta-analysis and trial sequential analysis. *BMC Infect Dis* **2024**; 24(1): 967.
542. Castanheira M, Mendes RE, Jones RN. Update on *Acinetobacter* species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. *Clin Infect Dis* **2014**; 59 Suppl 6: S367–73.

543. Lepak AJ, Trang M, Hammel JP, et al. Development of Modernized *Acinetobacter baumannii* Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches. *Antimicrob Agents Chemother* **2023**; 67(4): e0145222.
544. Wang P, Bowler SL, Kantz SF, et al. Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant *Acinetobacter baumannii*. *J Clin Microbiol* **2016**; 54(12): 2937–41.
545. Rumbo C, Gato E, Lopez M, et al. Contribution of efflux pumps, porins, and beta-lactamases to multidrug resistance in clinical isolates of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2013**; 57(11): 5247–57.
546. Yang YS, Lee Y, Tseng KC, et al. In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2016**; 60(7): 4047–54.
547. Lodise TP, Van Wart S, Sund ZM, et al. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). *Antimicrob Agents Chemother* **2021**; 65(3).
548. Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program's evaluation of minocycline for multidrug-resistant *Acinetobacter baumannii* infections. *Clin Infect Dis* **2014**; 59 Suppl 6: S381–7.
549. Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant *Acinetobacter* infections. *Clin Infect Dis* **2014**; 59 Suppl 6: S374–80.
550. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. *Intensive Care Med* **2003**; 29(11): 2072–6.
551. Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. *Medicine (Baltimore)* **2018**; 97(38): e12467.
552. Mei H, Yang T, Wang J, Wang R, Cai Y. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR *Acinetobacter baumannii*: a systematic review and meta-analysis. *J Antimicrob Chemother* **2019**; 74(12): 3423–31.
553. Zhang X, Xie Y, Liu F, et al. Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant *Acinetobacter baumannii*. *J Antimicrob Chemother* **2026**; 81(2).
554. Luo X, Wang S, Li D, Wen J, Sun N, Fan G. Population pharmacokinetics of tigecycline in critically ill patients. *Front Pharmacol* **2023**; 14: 1083464.
555. Xie J, Roberts JA, Alobaid AS, et al. Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. *Antimicrob Agents Chemother* **2017**; 61(8).

556. De Pascale G, Lisi L, Ciotti GMP, et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. *Ann Intensive Care* **2020**; 10(1): 94.
557. Noel AR, Attwood M, Bowker KE, MacGowan AP. In vitro pharmacodynamics of omadacycline against *Escherichia coli* and *Acinetobacter baumannii*. *J Antimicrob Chemother* **2021**; 76(3): 667–70.
558. Vanachayangkul P, Ruamsap N, Caridha D, et al. Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2025**; 69(12): e0093225.
559. Morrisette T, Alosaimy S, Lagnf AM, et al. Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens. *Infect Dis Ther* **2022**; 11(4): 1715–23.
560. Chen D, Chen Y, Hu N, et al. A matched pilot cohort study of intravenous omadacycline in the treatment of severe pneumonia associated with carbapenem-resistant *Acinetobacter baumannii*. *Front Microbiol* **2025**; 16: 1597860.
561. Fanning WL, Gump DW. Distressing side-effects of minocycline hydrochloride. *Arch Intern Med* **1976**; 136(7): 761–2.
562. Minocycline. FDA Drug Label. Food and Drug Administration.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e415c323-8219-464b-9e3e-72c5a796cdaa>. Accessed December 31, 2025.
563. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in *Acinetobacter baumannii* resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. *J Hosp Med* **2016**; 11(1): 21–6.
564. McKay SL, Vlachos N, Daniels JB, et al. Molecular Epidemiology of Carbapenem-Resistant *Acinetobacter baumannii* in the United States, 2013–2017. *Microb Drug Resist* **2022**; 28(6): 645–53.
565. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? *Clin Infect Dis* **2014**; 59(1): 88–94.
566. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in mouse thigh and lung infection models: smaller response in lung infection. *J Antimicrob Chemother* **2015**; 70(12): 3291–7.
567. Landersdorfer CB, Wang J, Wirth V, et al. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against *Klebsiella pneumoniae* in mouse thigh and lung infection models. *J Antimicrob Chemother* **2018**; 73(2): 462–8.
568. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* **2002**; 46(6): 1946–52.

569. Kaye KS, Marchaim D, Thamlikitkul V, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. *NEJM Evid* **2023**; 2(1).
570. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infect Dis* **2018**; 18(4): 391–400.
571. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant *Acinetobacter baumannii*: a multicenter, randomized clinical trial. *Clin Infect Dis* **2013**; 57(3): 349–58.
572. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant *Acinetobacter baumannii*: A randomised controlled trial. *J Glob Antimicrob Resist* **2019**; 17: 66–71.
573. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. *Epidemiol Infect* **2013**; 141(6): 1214–22.
574. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant *Acinetobacter baumannii*. *Scand J Infect Dis* **2007**; 39(1): 38–43.
575. Groschel MI, Meehan CJ, Barilar I, et al. The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist *Stenotrophomonas maltophilia*. *Nat Commun* **2020**; 11(1): 2044.
576. Wang N, Tang C, Wang L. Risk Factors for Acquired *Stenotrophomonas maltophilia* Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis. *Front Med (Lausanne)* **2021**; 8: 808391.
577. Aitken SL, Sahasrabhojane PV, Kontoyiannis DP, et al. Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With *Stenotrophomonas maltophilia* Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy. *Clin Infect Dis* **2021**; 72(9): 1507–13.
578. Karaba SM, Goodman KE, Amoah J, Cosgrove SE, Tamma PD. StenoSCORE: Predicting *Stenotrophomonas maltophilia* Bloodstream Infections in the Hematologic Malignancy Population. *Antimicrob Agents Chemother* **2021**; 65(8): e0079321.
579. Kunz Coyne AJ, Lucas K, Gray R, May E. Propensity-Matched Comparison of Timely vs Delayed Antibiotic Therapy in *Stenotrophomonas maltophilia* Pneumonia. *Open Forum Infect Dis* **2025**; 12(8): ofaf469.
580. Gezer Y, Taysi MR, Tarakci A, et al. Evaluation of clinical outcomes and risk factors associated with mortality in patients with *Stenotrophomonas maltophilia* bloodstream infection: a multicenter study. *BMC Infect Dis* **2024**; 24(1): 1387.
581. Khunkit P, Siripaitoon P, Lertsrisatit Y, et al. Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due to *Stenotrophomonas maltophilia*. *Antibiotics (Basel)* **2024**; 13(8).

582. Gajdacs M, Urban E. Prevalence and Antibiotic Resistance of *Stenotrophomonas maltophilia* in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot. *Health Serv Res Manag Epidemiol* **2019**; 6: 2333392819870774.
583. Cho SY, Lee DG, Choi SM, et al. *Stenotrophomonas maltophilia* bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. *BMC Infect Dis* **2015**; 15: 69.
584. Kim SH, Cha MK, Kang CI, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic malignancy patients with *Stenotrophomonas maltophilia* bacteremia: clinical and microbiological analysis. *Eur J Clin Microbiol Infect Dis* **2019**; 38(2): 285–95.
585. Imoto W, Yamada K, Yamairi K, et al. Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by *Stenotrophomonas maltophilia*. *Intern Med* **2020**; 59(2): 193–8.
586. Tada K, Kurosawa S, Hiramoto N, et al. *Stenotrophomonas maltophilia* infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. *Bone Marrow Transplant* **2013**; 48(1): 74–9.
587. Araoka H, Fujii T, Izutsu K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by *Stenotrophomonas maltophilia* in hematologic malignancy. *Transpl Infect Dis* **2012**; 14(4): 355–63.
588. Crossman LC, Gould VC, Dow JM, et al. The complete genome, comparative and functional analysis of *Stenotrophomonas maltophilia* reveals an organism heavily shielded by drug resistance determinants. *Genome Biol* **2008**; 9(4): R74.
589. Mojica MF, Rutter JD, Taracila M, et al. Population Structure, Molecular Epidemiology, and beta-Lactamase Diversity among *Stenotrophomonas maltophilia* Isolates in the United States. *mBio* **2019**; 10(4).
590. Lambert T, Ploy MC, Denis F, Courvalin P. Characterization of the chromosomal *aac(6')-Iz* gene of *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **1999**; 43(10): 2366–71.
591. Gordon NC, Wareham DW. Novel variants of the *Smqnr* family of quinolone resistance genes in clinical isolates of *Stenotrophomonas maltophilia*. *J Antimicrob Chemother* **2010**; 65(3): 483–9.
592. Alonso A, Martinez JL. Cloning and characterization of *SmeDEF*, a novel multidrug efflux pump from *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2000**; 44(11): 3079–86.
593. Sanchez MB, Martinez JL. Overexpression of the Efflux Pumps *SmeVWX* and *SmeDEF* Is a Major Cause of Resistance to Co-trimoxazole in *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2018**; 62(6).
594. Khan A, Pettaway C, Dien Bard J, Arias CA, Bhatti MM, Humphries RM. Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2023**; 95(5).

595. Khan A, Arias CA, Abbott A, Dien Bard J, Bhatti MM, Humphries RM. Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of *Stenotrophomonas maltophilia*. *J Clin Microbiol* **2021**; 59(9): e0065421.
596. Biagi M, Vialichka A, Jurkovic M, et al. Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2020**; 64(9).
597. Shortridge D, Streit JM, Mendes R, Castanheira M. In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. *Microbiol Spectr* **2022**; 10(2): e0271221.
598. Sakoh T, Miyajima E, Endo Y, et al. Cefiderocol susceptibility of 146 *Stenotrophomonas maltophilia* strains clinically isolated from blood in two Japanese hospitals over a 10-year period. *Eur J Clin Microbiol Infect Dis* **2024**; 43(12): 2485–8.
599. Mendez-Sotelo BJ, Delgado-Beltran M, Hernandez-Duran M, et al. In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the *Stenotrophomonas maltophilia* complex. *PLoS One* **2024**; 19(4): e0298577.
600. Sakr C, Danjean M, Cizeau F, et al. Unexpected natural cefiderocol resistance in *Stenotrophomonas maltophilia* associated to the genogroup 4 genetic background. *Clin Microbiol Infect* **2025**; 31(10): 1691–6.
601. Chen IH, Kidd JM, Abdelraouf K, Nicolau DP. Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against *Stenotrophomonas maltophilia* in the Murine Thigh Model. *Antimicrob Agents Chemother* **2019**; 63(12).
602. Nakamura R, Oota M, Matsumoto S, Sato T, Yamano Y. In Vitro Activity and In Vivo Efficacy of Cefiderocol against *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2021**; 65(4).
603. Petraitis V, Petraitiene R, Kavaliauskas P, et al. Efficacy of Cefiderocol in Experimental *Stenotrophomonas maltophilia* Pneumonia in Persistently Neutropenic Rabbits. *Antimicrob Agents Chemother* **2022**; 66(10): e0061822.
604. FDA Rationale for Recognition Decision: Cefiderocol. www.fda.gov/drugs/development-resources/fda-rationale-recognition-decision-cefiderocol. Accessed December 31, 2025.
605. Torre-Cisneros J, Ferrer R, Martos CF, et al. Cefiderocol treatment for patients infected by *Stenotrophomonas maltophilia*, *Burkholderia cepacia* complex and *Achromobacter* spp.: subgroup analysis from the PERSEUS study. *Eur J Clin Microbiol Infect Dis* **2025**; 44(6): 1367–74.
606. Vena A, Mezzogori L, Castaldo N, et al. Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by *Stenotrophomonas maltophilia*: A Case Series and Literature Review. *Infect Dis Ther* **2025**; 14(3): 657–69.

607. Lupia T, Carnevale-Schianca F, Vita D, et al. *Stenotrophomonas maltophilia* Infections in Haematological Malignancies and Hematopoietic Stem Cell Transplantation: A Case Series including Cefiderocol-Based Regimens. *Medicina (Kaunas)* **2024**; 60(1).
608. Ko JH, Kang CI, Cornejo-Juarez P, et al. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of *Stenotrophomonas maltophilia* infections: a systematic review and meta-analysis. *Clin Microbiol Infect* **2019**; 25(5): 546–54.
609. Biagi M, Lamm D, Meyer K, et al. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2020**; 64(12).
610. Mojica MF, Papp-Wallace KM, Taracila MA, et al. Avibactam Restores the Susceptibility of Clinical Isolates of *Stenotrophomonas maltophilia* to Aztreonam. *Antimicrob Agents Chemother* **2017**; 61(10).
611. Lin Q, Zou H, Chen X, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against *S. maltophilia* clinical isolates in vitro. *BMC Microbiol* **2021**; 21(1): 60.
612. Sader HS, Castanheira M, Arends SJR, Doyle TB. Antimicrobial susceptibility of *Stenotrophomonas maltophilia* from United States medical centers (2019–2023). *Antimicrob Agents Chemother* **2025**; 69(4): e0012425.
613. Tao L, Dahlquist A, Harris H, et al. Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-beta-lactamase-producing carbapenem-resistant gram-negative bacilli. *Antimicrob Agents Chemother* **2024**; 68(10): e0069324.
614. Sader HS, Duncan LR, Arends SJR, Carvalhaes CG, Castanheira M. Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary *Stenotrophomonas maltophilia* Isolates from Medical Centers Worldwide. *Antimicrob Agents Chemother* **2020**; 64(11).
615. Sader HS, Mendes RE, Doyle TB, Winkler ML, Castanheira M. Antimicrobial susceptibility of clinical isolates of *Stenotrophomonas maltophilia* from Europe, Asia, and Latin America (2018–2023). *Int J Infect Dis* **2025**; 153: 107803.
616. Calvopina K, Hinchliffe P, Brem J, et al. Structural/mechanistic insights into the efficacy of nonclassical beta-lactamase inhibitors against extensively drug resistant *Stenotrophomonas maltophilia* clinical isolates. *Mol Microbiol* **2017**; 106(3): 492–504.
617. Fu Y, Fouad A, Roenfanfz HF, Nicolau DP, Kuti JL. Efficacy of human-simulated aztreonam-avibactam against *Stenotrophomonas maltophilia* in the neutropenic murine thigh infection model. *J Antimicrob Chemother* **2025**; 80(12): 3431–7.
618. Mojica MF, Ouellette CP, Leber A, et al. Successful Treatment of Bloodstream Infection Due to Metallo-beta-Lactamase-Producing *Stenotrophomonas maltophilia* in a Renal Transplant Patient. *Antimicrob Agents Chemother* **2016**; 60(9): 5130–4.

619. Wong-So J, Magreault S, Carbonnelle E, et al. Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2025**; 69(8): e0017225.
620. Fan X, Chen F, Ruan Z, Li L. Therapeutic challenges in managing *Stenotrophomonas maltophilia* bloodstream infection in a renal dysfunction patient: a case study and literature review. *Front Cell Infect Microbiol* **2025**; 15: 1694228.
621. Diarra A, Pascal L, Carpentier B, et al. Successful use of avibactam and aztreonam combination for a multiresistant *Stenotrophomonas maltophilia* bloodstream infection in a patient with idiopathic medullary aplasia. *Infect Dis Now* **2021**; 51(7): 637–8.
622. Kunz Coyne AJ, Gray R, Gonnabathula P, May ES, Tamma PD, Do A. Comparative in vitro activity of aztreonam–avibactam and aztreonam plus ceftazidime–avibactam against *Stenotrophomonas maltophilia* complex. *Antimicrobial Agents and Chemotherapy*, 2025 (accepted for publication).
623. Holsken O, Sponheuer K, Weber F, et al. First Clinical Application of Aztreonam-Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations. *J Pers Med* **2024**; 14(12).
624. Sarzynski SH, Lawandi A, Warner S, et al. Association between minimum inhibitory concentration values and mortality risk in patients with *Stenotrophomonas maltophilia* infections: a retrospective cohort study of electronic health records from 148 US hospitals. *JAC Antimicrob Resist* **2023**; 5(2): dlad049.
625. Baek JH, Kim CO, Jeong SJ, et al. Clinical factors associated with acquisition of resistance to levofloxacin in *Stenotrophomonas maltophilia*. *Yonsei Med J* **2014**; 55(4): 987–93.
626. Nys C, Cherabuddi K, Venugopalan V, Klinker KP. Clinical and Microbiologic Outcomes in Patients with Monomicrobial *Stenotrophomonas maltophilia* Infections. *Antimicrob Agents Chemother* **2019**; 63(11).
627. Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating *Stenotrophomonas maltophilia* bacteremia? *Antimicrob Agents Chemother* **2014**; 58(1): 581–3.
628. Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of *Stenotrophomonas maltophilia* infections. *Antimicrob Agents Chemother* **2014**; 58(1): 176–82.
629. Garcia-Leon G, Ruiz de Alegria Puig C, Garcia de la Fuente C, Martinez-Martinez L, Martinez JL, Sanchez MB. High-level quinolone resistance is associated with the overexpression of smeVWX in *Stenotrophomonas maltophilia* clinical isolates. *Clin Microbiol Infect* **2015**; 21(5): 464–7.
630. Wu CJ, Lu HF, Lin YT, Zhang MS, Li LH, Yang TC. Substantial Contribution of SmeDEF, SmeVWX, SmQnr, and Heat Shock Response to Fluoroquinolone Resistance in Clinical Isolates of *Stenotrophomonas maltophilia*. *Front Microbiol* **2019**; 10: 822.

631. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in *Stenotrophomonas maltophilia*: involvement of a multidrug efflux system. *Antimicrob Agents Chemother* **2000**; 44(2): 287–93.
632. Fratoni AJ, Nicolau DP, Kuti JL. Levofloxacin pharmacodynamics against *Stenotrophomonas maltophilia* in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. *J Antimicrob Chemother* **2021**; 77(1): 164–8.
633. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of *Stenotrophomonas maltophilia* clinical isolates. *J Antimicrob Chemother* **2000**; 45(1): 115–7.
634. Grillon A, Schramm F, Kleinberg M, Jehl F. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. *PLoS One* **2016**; 11(6): e0156690.
635. Wei C, Ni W, Cai X, Cui J. A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by *Stenotrophomonas maltophilia*. *Infect Dis (Lond)* **2015**; 47(12): 846–51.
636. Imoto W, Kaneko Y, Yamada K, et al. A mouse model of rapidly progressive fatal haemorrhagic pneumonia caused by *Stenotrophomonas maltophilia*. *J Glob Antimicrob Resist* **2020**; 23: 450–5.
637. Sarzynski SH, Warner S, Sun J, et al. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for *Stenotrophomonas maltophilia* Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals. *Open Forum Infect Dis* **2022**; 9(2): ofab644.
638. Almangour TA, Alkherb Z, Alruwaite S, et al. Trimethoprim-sulfamethoxazole versus levofloxacin for the treatment of *Stenotrophomonas maltophilia* infections: A multicentre cohort study. *J Glob Antimicrob Resist* **2024**; 38: 42–8.
639. Boonmee P, Nasomsong W, Lorchirachoonkul N, et al. The Activities of Antimicrobials Against *Stenotrophomonas maltophilia* Isolates and Evaluation of Clinical Outcomes Among Treatment Regimens in Patients with *Stenotrophomonas maltophilia* Infections: A Retrospective Multicenter Cohort Study. *Infect Drug Resist* **2023**; 16: 5173–84.
640. Muder RR, Harris AP, Muller S, et al. Bacteremia due to *Stenotrophomonas* (*Xanthomonas*) *maltophilia*: a prospective, multicenter study of 91 episodes. *Clin Infect Dis* **1996**; 22(3): 508–12.
641. Graves ET, Wardlow L, Ogake S, et al. Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of *Stenotrophomonas maltophilia* pneumonia. *J Antimicrob Chemother* **2025**; 80(4): 988–95.
642. Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of *Stenotrophomonas maltophilia* infections. *J Antimicrob Chemother* **2016**; 71(4): 1071–5.

643. Tekce YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in *Stenotrophomonas maltophilia* infections. *J Chemother* **2012**; 24(3): 150–4.
644. Lai JJ, Siu LK, Chang FY, et al. Appropriate antibiotic therapy is a predictor of outcome in patients with *Stenotrophomonas maltophilia* blood stream infection in the intensive care unit. *J Microbiol Immunol Infect* **2023**; 56(3): 624–33.
645. Almangour TA, Alali HA, Alkherb Z, et al. Monotherapy versus combination for the treatment of *Stenotrophomonas maltophilia*: a multicenter cohort study. *Expert Rev Anti Infect Ther* **2024**; 22(11): 997–1005.
646. Curry H, Casaus D, Lucas K, Kunz Coyne AJ. Comparative evaluation of definitive therapy for deep-seated *Stenotrophomonas maltophilia* infections. *JAC Antimicrob Resist* **2025**; 7(6): dlaf215.
647. Gatti M, Bianchin M, Raschi E, De Ponti F. Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. *Eur J Intern Med* **2020**; 75: 60–70.
648. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. *Antimicrob Agents Chemother* **1997**; 41(10): 2256–60.
649. Gould VC, Okazaki A, Avison MB. Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* **2013**; 57(1): 655–7.
650. Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant *Stenotrophomonas maltophilia* by In Vitro Time-Kill Experiments. *PLoS One* **2016**; 11(3): e0152132.
651. Fratoni AJ, Nicolau DP, Kuti JL. Minocycline pharmacodynamics against *Stenotrophomonas maltophilia* in the neutropenic murine infection model: implications for susceptibility breakpoints. *J Antimicrob Chemother* **2022**; 77(4): 1052–60.
652. Hevia EC, Wooten L, Carr AL. Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial *Stenotrophomonas maltophilia* Infections in Hospitalized Patients. *Ann Pharmacother* **2024**; 58(7): 698–704.
653. Junco SJ, Bowman MC, Turner RB. Clinical outcomes of *Stenotrophomonas maltophilia* infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy. *Int J Antimicrob Agents* **2021**; 58(2): 106367.
654. Jacobson S, Junco Noa L, Wallace MR, Bowman MC. Clinical outcomes using minocycline for *Stenotrophomonas maltophilia* infections. *J Antimicrob Chemother* **2016**; 71(12): 3620.
655. Wu J, Zhang G, Zhao Q, Wang L, Yang J, Cui J. In vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and/or

Trimethoprim-Sulfamethoxazole-Resistant *Stenotrophomonas maltophilia*. *Infect Drug Resist* **2023**; 16: 6005–15.

656. Biagi M, Tan X, Wu T, et al. Activity of Potential Alternative Treatment Agents for *Stenotrophomonas maltophilia* Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole. *J Clin Microbiol* **2020**; 58(2).
657. Cai B, Tillotson G, Benjumea D, Callahan P, Echols R. The Burden of Bloodstream Infections due to *Stenotrophomonas Maltophilia* in the United States: A Large, Retrospective Database Study. *Open Forum Infect Dis* **2020**; 7(5): ofaa141.
658. Hu LF, Chen GS, Kong QX, et al. Increase in the Prevalence of Resistance Determinants to Trimethoprim/Sulfamethoxazole in Clinical *Stenotrophomonas maltophilia* Isolates in China. *PLoS One* **2016**; 11(6): e0157693.
659. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in *Stenotrophomonas maltophilia* mediated by acquisition of sul genes. *Emerg Infect Dis* **2007**; 13(4): 559–65.
660. Lasko MJ, Gethers ML, Tabor-Rennie JL, Nicolau DP, Kuti JL. In Vitro Time-Kill Studies of Trimethoprim/Sulfamethoxazole against *Stenotrophomonas maltophilia* versus *Escherichia coli* Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. *Antimicrob Agents Chemother* **2022**; 66(3): e0216721.
661. Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of *Stenotrophomonas maltophilia*. *Diagn Microbiol Infect Dis* **2005**; 51(1): 39–43.
662. Lasko MJ, Tabor-Rennie JL, Nicolau DP, Kuti JL. Trimethoprim/sulfamethoxazole pharmacodynamics against *Stenotrophomonas maltophilia* in the in vitro chemostat model. *J Antimicrob Chemother* **2022**; 77(11): 3187–93.
663. Preyra R, Eddin LE, Ahmadi F, Jafari A, Muanda FT. Safety of sulfamethoxazole-trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta-analysis with active comparator disproportionality analysis. *Br J Clin Pharmacol* **2025**; 91(6): 1632–48.
664. Klepser ME, Zhu Z, Nicolau DP, et al. Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. *Pharmacotherapy* **1996**; 16(4): 656–62.